Health workers in full protective gear do a COVID-19 throat swab in a Addis Ababa isolation centre. But in Kampala, Uganda, doctors have no suits and they must to purchae their own masks.

CAPETOWN, South Africa – As many African countries opt for lockdowns to combat COVID-19, there is uncertainty over whether this will be enough to prevent the pandemic’s spread, or whether authorities will be able to implement this in overcrowded urban areas – as well as fears for patients with HIV, TB and other conditions that require monthly medication.

There is a sense that Africans are on the shore watching the sea drawing back before the tsunami of infections hit, overwhelming the continent’s health facilities and killing thousands of people.

In late February,  just a handful of African countries had recorded a few COVID-19 cases. Egypt, Algeria and South Africa, with a high volume of air traffic from other affected regions of the world, were hit first.

By yesterday (29 March), 4,282 cases of the virus had been recorded in 46 of the 54 African countries, according to the Africa Centres for Disease Control and Prevention (CDC).

WHO’s Director-General, Dr Tedros Adhanom Ghebreyesus recently warned the continent to “prepare for the worst”.

African countries have been struggling to reconcile measures to arrest the virus, such as travel bans, social distancing and restricting public gatherings, with the need to protect their weak economies.

More African Countries Using Lockdown Measures 

Amid the growing consensus that China’s reversal of its pandemic started from a lockdown, and this is the most effective way to reverse the pandemic, key African countries have opted for drastic  measures to contain the virus in the past few days.

Rwandans are in a 14-day lockdown which started on 22 March. Kenya has a night-time curfew and restrictions on gatherings.

South Africa went into a 21-day total lockdown on Friday.

Soweto, South Africa. Poverty and crowded conditions make lockdowns doubly difficult.

“Those countries that have acted swiftly and dramatically have been far more effective in controlling the spread of the disease,” said South African President Cyril Ramaphosa.

“While this measure will have a considerable impact on people’s livelihoods, on the life of our society and on our economy, the human cost of delaying this action would be far, far greater.”

The Democratic Republic of Congo implemented a four-day lockdown on Saturday, after the move had been delayed for a few days when the prices of essential goods spiked.

Yesterday, Nigeria’s president Muhammadu Buhari announced a 14-day lockdown for Lagos and Ogun state which comes into effect at 11pm Monday, 30 March.

Ghanians living in Accra and Kumasi face a two-week lockdown from today. Zimbabweans also face a 21-day lockdown from today, and Lesotho citizens face a 25-day lockdown. Congo-Brazzaville goes into lockdown from tomorrow (Tuesday) and eight towns in Burkina Faso will be shut down from Friday for 14 days.

However, implementing the lockdowns has proven challenging.

South Africans may only leave their homes to buy basic groceries or medical supplies and there is a ban on the sale of alcohol. The South African National Defence Force has been brought in to support the police. Already, police used rubber bullets and water cannons to disperse shoppers in Johannesburg who were refusing to stand an arm’s length apart.

Two Rwandans were reported to have been shot dead over the weekend, although that government subsequently denied that the shootings were related to the lockdown.

Observers also fear that the heavy-handed application of lockdown measures, in the African context, will deprive people of access to food and essential services, including essential medical care.

One worried Ugandan doctor who contacted Health Policy Watch related the story of an expectant mother living in a village some distance from Kampala, who had called him shortly after the country’s lockdown was announced on Monday, fearing that she was going into labour.

“She has poor obstetric history,” he said. “A few days ago, she did an ultrasound scan that revealed a breech presentation. Her expected date of delivery is 3 April. She cannot access medical services since she is in the village, in a distance not walkable to the nearest facility where she can have ceaserian section done (if necessary).

“‘I can not afford an ambulance because drivers often need fuel facilitation,’ she lamented. I was left speechless… She is opting to walk to the nearest traditional birth attendant for some magic. I felt this is worth sharing.”

 

COVID-19 simulation exercise at the Kinshasa International Airport, Democratic Republic of Congo.

Some Front-Line Health Workers Aren’t Getting PPE Supplies – Despite Massive WHO Shipments 

Meanwhile, epidemics experts are urging African governments to do whatever they can to protect the continent’s thin line of health workers. They urgently need personal protective equipment (PPE) such as masks, gloves and hand sanitiser.

“But other measures are very important such as ventilation, spacing, early triage and separation of potential cases and increased access to water and supplies,” said Amanda McClelland, senior vice-president of PreventEpidemics, part of Vital Strategies’ Resolve to Save Lives programme.

Dr Gilles van Cutsem, an infectious disease doctor and epidemiologist with Médicins sans Frontières (MSF), stressed that “there needs to be planning and preparation for screening and triage at health facilities to avoid overcrowding and saturation of hospitals, and ensure that hospitals do not become foci of transmission”.

“In Italy and China triage tents were set up outside hospitals to receive and separate patients,” added van Cutsem.

Meanwhile, HIV clinician Dr Francois Venter, deputy director of Reproductive Health and HIV Institute Johannesburg, urged those who are “mildly symptomatic” to stay away from health facilities to make sure that there is space for the very sick.

Speaking after 14 days in quarantine, Venter said he had “anticipatory anxiety” as he waited for the deluge of patients.

“I was almost disappointed that my [COVID-19] test was negative. For the first time in my life, I understand emotionally the relief that some of my gay clients expressed when they finally tested positive for HIV,” said Venter.

While the WHO has reportedly sent large consignments of PPE to various African countries, shortages are still being reported all over the continent.

There were only 60 N95masks distributed to some 280 health workers at China-Uganda Friendship Hospital near Kampala, a designated treatment facility for Covid-19 patients.  Doctors and nurses performing COVID-19 tests have to purchase their own masks, according to one staff member, assigned to the COVID-19 isolation unit. That, despite the fact a WHO African “Readiness” Checklist showed Uganda to be equipped with masks and gloves.

WHO Readiness Checklist shows Uganda equipped with PPE. Frontline health workers in Kampala isolation unit say they must buy their own masks.

The hospital staff only received gloves after threatening to go on strike – although when gloves run short, patients are also asked to purchase them in order to be examined.

When asked by Health Policy Watch about the reports of PPE shortages in Uganda’s COVID-19 units, WHO did not comment. Nor did it provide aggregate totals of PPE supplies that have been shipped to Africa until now.

However, in a press briefing Monday, WHO Emergencies Head Mike Ryan said, “”We have already sent large numbers of PPE and diagnostics to the countries. It’s not enough. We are working with World Food Programme, Jack Ma Foundation, and Africa CDC to bring in PPE.”  Jack Ma, founder of the Alibaba Group, is making a series of massive donations to regions across the world, including 1.1 million test kits, 6 million masks and 60,000 protective suits for Africa, which were due to begin distribution last week, according to Ethiopia’s Prime Minsiter, Abiy Ahmed Ali.

Donations of PPE from by the Jack Ma Foundation land in Addis Ababa last week.

McClelland recently returned from Ethiopia, Africa’s second most populous African country, and has few illusions about the massive tasks that lie ahead: “There is still much more to do in Ethiopia to test and detect cases. The extent of transmission in this country with 105 million people is not really known.”

There are two major challenges: preparing and training health workers – Ethiopia only has 19,000 – and engaging communities to change their personal behaviour to limit the spread.

Sobering new data from Imperial College predicts that 250 critical care beds will be needed per 100, 000 people if the non-pharmaceutical interventions, such as social distancing and restricting gatherings, are not successful in stemming the tide of infections.

A recent report from Nigeria estimates that the country may only have around 500 ventilators for a population of over 200-million.

Said Ryan, “The issue of ventilators is very important – but from the perspective of supporting patients, oxygen is also something we need to discuss.“Before ventilator support, what truly is lifesaving is the ability to give patients supplemental oxygen. When someone has COVID19 your lungs struggle to put oxygen in your blood. Every country in Africa has oxygen. We need to focus on getting better distribution of lifesaving oxygen. We are working to scale up the distribution of supplies and coordinate in a way that countries can expect a smooth service.”

“Micro-Isolation” Tactics Used For Ebola May Help Contain COVID-19 

While COVID-19 is a different kind of infection, with effects likely to eclipse the more deadly but less contagious diseases such as Ebola, the continent has learnt important lessons about epidemics from its experiences battling such viruses steadily, including during the 2014-2016 health emergency in West Africa, as well as the more 2018-2020 Ebola epidemic in DRC, now finally on the wane.

While trying to contain Ebola, Guinea introduced a form of community quarantine called “micro-cerclage” (micro-encirclement) to limit the movement of people in Ebola-affected areas.

Those showing symptoms of Ebola were placed in isolation while those close to them were asked to limit their movements. Limited essential movement – such as attending to crops – was allowed and was often monitored by people’s mobile phones.

Amanda McCelelland, Prevent Epidemics

Community leaders’ support for the policy was key, as were local response teams who enforced the monitoring. Affected households were also provided with food and basic toiletries.

“Microcerclage is one approach that will potentially add real value to addressing COVID-19 but this will depend on the scale of community transmission,” says McClelland, who came face-to-face with Ebola while working in the Emergency Health Unit of the International Federation of Red Cross and Red Crescent Societies.

“If clusters can be detected early and isolated then this approach could help communities to not be negatively impacted and to continue to have access to key services and resources including food and water.”

But a huge challenge is how to quarantine city dwellers. Over 20 million people live in crowded conditions in Lagos, five million live in Johannesburg and three million in Addis Ababa.

“Self-isolation and restriction of population movement on a much larger scale in some cities would stretch the resources to be able to provide food, water and services on a citywide scale,” warned McClelland.

Community Engagement Also Key 

Ebola also has negative lessons. “Without community engagement and trust, the outcomes can be devastating,” warned McClelland. “In the Ebola response, this tragically included violence against first responders. We must do everything we can to avoid this in the response to COVID-19.”

In 2019 in the DRC alone, MSF recorded more than 300 attacks on Ebola health workers, during which six people were killed and 70 wounded.

Stigmatising foreigners assumed to be infected with COVID-19 is already happening.

On 18 March, the US embassy in Ethiopia issued a security alert warning of “a rise in anti-foreigner sentiment revolving around the announcement of COVID-19”.

“Incidents of harassment and assault directly related to COVID-19 have been reported by other foreigners living within Addis Ababa and other cities throughout the country. Reports indicate that foreigners have been attacked with stones, denied transportation services, being spat on, chased on foot, and been accused of being infected with COVID-19,” according to the Embassy.

Laboratory capacity has also been improved in many Ebola-affected countries, and Nigeria in particular has made substantial improvements in combating epidemics in the last few years.

But Van Cutsem warned that the laboratory capacity of most African countries, aside from South Africa is “extremely poor”.

“Countries have to find ways to improve the capacity of their laboratories to process tests, and we need the introduction of rapid tests,” said Van Cutsem.

While some African leaders have speculated that the virus may not survive in high temperatures, McClelland simply says: “The short answer is we do not know yet. The science is still not clear. There is some evidence that, in a laboratory , the virus may be affected by warmer temperatures. But we also have transmission occurring in warm climates like Australia, the Middle East and South East Asia. Influenza transmits all year round in much of Africa and can actually be worse in dusty conditions. It is too early to assume Africa is protected due to heat and they must prepare with the same sense of urgency as other countries.”

Hopes that the pandemic may be short-lived are not shared by experts who quietly talk about the current conditions continuing for many more months.

“Settle down to this. Social isolation might be the new normal for the rest of the year. Look after your mental health, check in with people and be kind,” advises Venter.

At the same time, in Africa, where large proportions of the population live below or on the verge of poverty, ensuring people’s basic needs during the COVID-19 emergency, will still remain the most fundamental priority, said Dr Tedros Adhanom Ghebreyesus, in a brieing Monday.

“Some countries have strong social welfare systems, some countries don’t. I’m from Africa as you know, and I know some people have to work every single day to win their daily bread. And governments have to take this into account. If we are closing and limiting movement, what will happen to people who have to work on a daily basis? We don’t mean the effect as an average of GDP loss or general effect on the economy; we have to see what it means to an individual on the street.”

Kerry Cullinan is the health editor for openDemocracy 50.50, and based in South Africa.

-Updated 31 March, 2020

Image Credits: Matt-80, © WHO/Otto B., © WHO/Kabambi E., Twitter: @AbiyAhmedAli , Vital Strategies , Courtesy of Kerry Cullinan.


Warning: Attempt to read property "post_title" on null in /home/clients/58f2a29976672af522a8f4d82ffa28b6/web/wp-content/plugins/better-image-credits/better-image-credits.php on line 227

Warning: Attempt to read property "post_title" on null in /home/clients/58f2a29976672af522a8f4d82ffa28b6/web/wp-content/plugins/better-image-credits/better-image-credits.php on line 227
(HPW/Svet Lustig): How countries rank in COVID-19 tests/per million population. Based on national test data collected by FIND (finddx.org), 28 March, 2020.

Testing: the crux of effective outbreak responses

Testing is an essential component of effective outbreak responses. Without widespread testing, we cannot know whether a disease is spreading nor take measures to appropriately respond to it. All countries should be able to test all suspected cases, they cannot fight this pandemic blindfolded, they should know where the cases are, and that is how they can take decisions,” said Dr Tedros, WHO Director General. Health Policy Watch is tracking testing trends in countries around the world, based on data from FIND’s COVID-19 tracker.

We display diagnostic capacity using two measures – cumulative testing by countries and trends showing change  

We have displayed the data using two measures: cumulative number of tests per million population, for all countries administering tests as of 28 March, and trends in selected countries over the past week.

From the cumulative data, we can see how some countries, including Iceland, Bahrain, Norway, the United Arab Emirates, and Switzerland, far outpace other nations in terms of their rate of testing, per million people. We also see how many low and middle income countries across Africa, Latin America and South-East Asia still lack any significant test capacity, even while cases are rising.  Importantly, we present testing data per million people to account for large population differences between countries.

From the trends data, we can also see how countries such as Australia, Switzerland and the United States, have very rapidly ramped up testing over just the past week, while others, such as France and Great Britain, lag further behind.

Testing Trends In Europe
Within the past week, European countries such as Switzerland and the Czech Republic have doubled and tripled their testing capacity, respectively. Switzerland, which has one of the highest per-capita rates of infection in the world, has now administered 12,639 tests per million people. Countries like France and the UK, however, have not reported any changes in testing over the past week, with only 1,548 and 1,779 tests per million , respectively, despite increasingly high infection rates.
(HPW/Svet Lustig): Trends in selected countries of WHO’s European Region. Based on national test data collected by FIND (finddx.org), 28 March, 2020.

Western Pacific, Eastern Mediterranean and Americas Regions – High Income

Australia has sharply increased its testing, with 8,134 tests per million on 28 March, double that of a week ago. While the USA has almost quadrupled its testing capacity in one week, it still has only administered a total of 2,032 tests per million, lagging behind many high-income regions.  Trends covered are in selected high income countries of the region.

(HPW/Svet Lustig): Trends in selected low- and middle-income countries of WHO’s Western Pacific (WPRO), Eastern Mediterranean (EMRO) and Americas (AMRO) regions. Based on national test data collected by FIND (finddx.org), 28 March, 2020.

African, South-East Asian and Americas Regions – Low & Middle Income  

Trends here are for selected low- and middle-income coutnries that are testing significantly. In the African continent, South Africa leads with 539 tests per million. While South Africa’s testing capacity is still low in comparison to the rest of the world, this is still approximately double compared to last week.
In Latin America, Chile has increased its testing five-fold for a cumulative total of 1209 tests per million; followed by Costa Rica, which has doubled its testing capacity to 600 tests per million. While testing capacity has almost doubled in India, as well, the country so far carried out only 20 tests per million people.
(HPW/Svet Lustig): Trends in selected low- and middle-income countries of WHO’s Americas (AMRO), African AMRO) and South East Asia (SEARO) regions. Based on national test data collected by FIND (finddx.org), 28 March, 2020.

 

Transmission electron micrograph of SARS-CoV-2 (red), the virus that causes COVID-19

Some 33 Members of the European Parliament released an open letter Friday urging top leadership in the European Commission (EC) to prohibit exclusive licensing for COVID-19 products developed with European Union (EU) grants, and demanding transparency in the research and development pipeline to ensure affordability commitments are met. 

In a separate letter signed by 37 NGOs and over 50 experts in health and patent law, public health and medicine, called on the World Health Organization and all Member States to get behind Costa Rica’s initiative to “pool” COVID-19 patent rights for essential drugs, vaccines, and technologies. The letter was posted by Knowledge Ecology International, a global patent watchdog group.

Those campaigns come right in the wake of the World Health Organization Director-General Dr Tedros Adhanom Ghebreyesus’ Twitter endorsement of Costa Rica’s call to create the “pooled rights” initiative.  

“We cannot allow patients to be refused care because of financial constraints or shortages resulting from manufacturing or supply constraints,” said the Members of the European Parliament in the letter addressed to EC President Ursula Von Der Leyen; EU Commissioner for Innovation, Research, Culture, and Youth, Mariya Gabriel; and EU Health and Food Safety Commissioner, Stella Kyriakides. 

Although the European Commission invests more than double of any private sector partner in EU-funded COVID-19 research, most of the calls for proposals so far do not seem to require companies or organizations to commit to affordability and access clauses, the MPs stated in their letter. Thus, it is even more important to enforce public oversight on the R&D process and bar exclusive licensing, they noted.

For new products, companies should be required to commit to non-exclusive licensing on any developed health technology as a precondition for receiving EU funding, said the MPs.  Granting exclusive licenses on new products could result in subsequent shortages, as only “one or very few companies” would be “allowed to produce an extremely timely medicine that is required in huge quantities worldwide,” the MPs stated.  

“From this moment forward, we require new medical tools to be immediately available once authorised for use, at an affordable price and in high enough quantities to meet global demand.”

Responding to the calls, Thomas Cueni, director-general of the International Federation of Pharmaceutical Manufacturers and Associations warned that pooling patent rights would not likely enhance the global battle against the virus. 

“While voluntary pooling of intellectual property and other assets can be a tool to stimulate R&D and facilitate access under certain conditions, its effects to address the current pandemic will likely be very limited,” warned Cueni in a statement. “Tools already exist for governments to access the medicines they need, and they are already being used in a number of cases. 

“In addition, there are established organizations in place –  such as the Medicines Patent Pool, a UN-backed initiative that uses a voluntary licensing and ‘pooled’ patent model to grant licenses to generics manufacturers – who have the expertise in licensing and managing an established pool of intellectual property assets,” Cueni added.

As one such example, AbbVie Pharmaceuticals recently announced that it would offer through the Medicines Patent Pool licenses for its lopinavir/ritonavir drug combination without patent restrictions, after the HIV treatment was identified by the World Health Organization as one of the drug combinations to be tested in a multi-country trial against COVID-19.

“Given the gravity and urgency of the COVID-19 pandemic, the biopharmaceutical industry has not wasted any time or spared any effort in using its skills, technology and resources to bring safe and effective treatments, vaccines and diagnostic to patients around the world as a matter of utmost urgency,” added Cueni, pointing to a list of IFPMA commitments on the emergency.

Civil Society Advocates Propose “Phased” Development of COVID-19 Patent Pool

However, the proposed pool of patent rights for COVID-19 technologies would, in fact, build on the successes of the Medicines Patent Pool in expanding affordable access to medicines for HIV/AIDS, tuberculosis, and hepatitis C, said Brook Baker, senior policy analyst at the Global Access Project, and a signatory on the KEI letter.

“Simply put, no exclusive rights should stand in the way of governments’ and the global community’s response to the COVID-19 pandemic,” Baker wrote in an opinion to Health Policy Watch on Costa Rica’s call to pool rights to drug development.

To build agreement around the roll-out of a COVID-19 patent pool, the KEI letter also proposes a phased approach. An initial “phase-one” agreement would establish the minimum legal basis to permit such licensing in the future, and create a process for working out the details. Hammering out which technologies to share, the terms of authorization, and possible remuneration for the pooled licenses could be done at a later date, the KEI signatories suggest. 

However, the pool for COVID-19 products should go beyond medicines patents, per se, to address regulatory test data, research data, cell lines, basic science innovations, and other intellectual property, the signatories, including some 37 NGOs and 50 experts.

Inputs to such a pool could come from governments that fund research and development or buy innovative products, as well as from universities, research institutes, charities, private companies and individuals who control rights, the letter suggests.

In parallel moves, two other large NGOs, Médecins Sans Frontières and the Treatment Action Group released separate public statements Friday calling for national governments to prepare to override patent protections as well as to take other measures, such as enacting price controls, to ensure availability of COVID-19 medicines, vaccines, and other medical tools. 

TAG threw its weight behind the MSF call, earlier in the week, for a US $5 price tag on a rapid COVID-19 test that can be used on the GeneXpert TB platform, which has thousands of diagnostics instruments in Africa, Latin America and South-East Asia.

“We know too well from our work around the world what it means to not be able to treat people in our care because a needed drug is just too expensive or simply not available,” said Dr Márcio da Fonseca, Infectious Disease Advisor at MSF’s Access Campaign in the statement.

South Africa, one of the first middle-income countries to embrace the Cepheid COVID-19 test, announced that it will begin using the new GeneXpert COVID-19 tests to leverage the large network of over 180 machines in the country to ramp up rapid testing, as total confirmed cases in the country crossed the 1000 cases threshold. The first test cartridges will be available for use in April.

Ad for generic lopinavir/ritonavir HIV drug combination, originally marketed as Kaletra by AbbVie, which relinquished its patent rights to the COVID-19 campaign

First Patient in WHO’s COVID-19 SOLIDARITY Trial Enrolled in Norway

At the University of Oslo Hospital in Norway, the first patient was enrolled Friday in WHO’s massive multi-country SOLIDARITY trial to collect data on potential COVID-19 treatments. This followed on an announcement by Prime Minister Erna Solberg of a 2.2 billion NOK (US$ 211) additional investment into the Coalition for Epidemic Preparedness Innovations (CEPI) COVID-19 vaccine development efforts. That was in addition to a 1.6 billion NOK (US$ 153.6 million) investment in the Oslo-based CEPI vaccine efforts.

“We are in a global quest for knowledge unlike anything we’ve ever seen,” said Noweigian Minister of Health Bent Høie in a press briefing. “We can save lives, protect healthcare professionals and all others from getting the disease.”  

The Norwegian SOLIDARITY trial patient will be the first to take part in this WHO-organized global effort to test four potential COVID-19 treatments under a simplified protocol, so that even low-resourced healthcare facilities could participate. The drugs to be tested include Gilead’s experimental drug remdesivir; the lopinavir/ritonavir originally developed by AbbVie Inc. for HIV/AIDs along with beta interferon; as well as the anti-malarials chloroquine or hydroxychloroquine with azithromycin. Another arm of the trial is also starting on Friday in Spain.

The SOLIDARITY Trial began as global case counts surpassed half a million, and total deaths surged over 26,000.

“These are tragic numbers,” said Dr Tedros.

Some countries are already administering the medications ad-hoc on a compassionate use basis, as well as stockpiling for future mass use. But WHO’s Dr Tedros has cautioned against widespread use of such treatments without strong evidence – following media reports of people self-medicating with the substances or ones similarly named. One man in the United States, for instance, died after ingesting chloroquine phosphate, a chemical used in aquarium cleaning, following US President Donald Trump’s endorsement of chloroquine as a treatment for COVID-19, according to the Associated Press.

“We call on individuals and countries to refrain from using therapeutics that have not been demonstrated to be effective in the treatment of COVID-19,” said Dr Tedros. “The history of medicine is strewn with examples of drugs that worked on paper, or in a test tube, but didn’t work in humans or were actually harmful.” 

In one example, he said that “during the most recent Ebola epidemic, for example, some medicines that were thought to be effective were found not to be as effective as other medicines when they were compared during a clinical trial.

“We must follow the evidence. There are no short-cuts.”

Contrary to WHO’s cautious approach, a prominent bioethicist suggested a radical approach to fast-tracking vaccine development – purposefully infecting young healthy volunteers with the virus and seeing whether the vaccine protects against infection. In a preprint paper, Director of the Center for Population–Level Bioethics (CPLB) at Rutgers University Nir Eyal suggested that despite placing participants at risk of “severe disease and death”, such a ‘human challenge’ study design could “subtract many months” from the vaccine licensure process, reducing the global burden of coronavirus morbidity and mortality.

COVID-19 cases worldwide as of Friday evening. Numbers change rapidly.

Image Credits: NIAID.

Health workers in Lecco, Lombardy, Italy in full protective gear.

No illusion.  COVID-19 is closer to us than we may imagine. And getting closer day by day. Around the world, in big cities and small centres alike, people are heading deeper into a sort of dystopian fiction, as if empty streets, latex gloves, face masks and self isolation were the new normal.

Some 1.3 billion Indians have been asked to stay home to fight the spread of the disease. One third of humanity is under Coronavirus lockdown. Never before has a virus stopped the entire world’s gears quite like this. 

The media of the entire planet is gripped by this new coronavirus, spreading a global panic – although we are also beginning to see governments step up response and engineer mass planning for worst-case scenarios. As it should be. The repercussions, however, are also moving the global health sphere into business and politics. 

The COVID-19 shockwave will end, at one point. Meanwhile, it is forcing a Copernican re-thinking of the interconnected global economy we have had in place for over three decades.

COVID-19 is not the first wake-up call for the world of the 21st century. The first seismic shock came with the terrorist attack of 9/11, followed by a global financial crisis which boiled over in 2008, with the collapse of Lehman Brothers.

Yet again, this invisible and silent virus – a minuscule RNA packet enveloped in a protein capsule – has shaped up to be an enormous stress test for globalization, shaking up all our institutional certainties as well as our individual lives. We are re-discovering just how vulnerable nations and people are. Just how fragile the globalized economy is, with its productive arrangements.

In his latest book on inequalities, Walter Scheidel reminds us that epidemics are one of the most transformative events in human history. Nothing new under the sun, basically, except that we don’t seem to learn the cogent lessons that the past, including the recent past, offers us. 

Since the start of the millennium we’ve seen a number of coronavirus species make the leap from animals to humans. The first occurred in China with SARS in 2002-2003, then in 2012 with MERS in Saudi Arabia and Jordan. Other virus specie leaps hae occurred with swine flu (H1N1) in 2009, bird flu in 2013 and 2017 (H7N9), as well as other pathogens such as Zika and Ebola (still active in Africa). For decades, experts from the science community have warned about the need to prepare for another pandemic like the 1918 Spanish flu (“the Great Influenza”), which killed at least 50 million people worldwide, but their premonitions went unheeded. 

Now that we are in it, SARS-CoV2 looks pretty much like the pathogen for which scientists had been waiting. It kills healthy adults as well as elderly people. Covid-19’s global fatality rate doubled over the past two months – up from 2.1% as of 20th January to 4.4% as of 23rd March, according to data of the World Health Organization (WHO). 

That is is much higher than 2% of the Spanish flu pandemic, although clearly, we still lack reliable evidence on how many people have been infected. The WHO recommendation (“Test, test, test”) has been key to the success in countries like South Korea, Singapore, Honk Kong and Iceland, which implemented widespread initiatives to test thousands of their inhabitants a day, early into the outbreak, thereby keeping numbers under control.

Overall, Europe’s variety of approaches, largely dependent on test kit availability or shortages as well as the limits of national health system capacity. This, in turn, has been a significant factor in the epidemiological tracking of the disease, as well as where it hit the hardest. Making testing quickly available has formed the basis of Germany’s strategy to combat the virus; COVID-19 tests have been available through the country’s statutory healthcare since January. Expansion of testing in France occurred only after lockdown, as the death toll increased. The same trend became apparent in Spain, where the death toll last week was doubling every three days.

Italy, the first country in Europe to experience a serious domestic surge of COVID-19 cases, and still the region’s major epicentre, has had to negotiate across a variety of sub-national approaches to testing, which make today’s estimates of the national mortality rate quite unreliable, as many mild or asymptomatic cases go uncounted. The lessons from Italy’s COVID-19 mistakes need to be shared widely.  However, differences in the number of people who are tested for the coronavirus and how deaths are recorded, limit the comparability of published data across even European countries to a large extent. 

What we certainly know by now is that the virus has an exponential transmission rate: one affected person may pass it on to 2-3 people, 10 people if the vector is a doctor or a nurse. The efficiency of the contagion is also  apparent among symptomless and pre-symptomatic individuals, or people with few symptoms   This means that COVID-19 is much harder to contain than SARS, which had a slower transmission rate, and only through symptomatic people. COVID-19 has already caused 10 times more cases than SARS, in just one-quarter of the time. 

When the emergency ebbs, we shall no longer recognize the landscape. Yet, in the reflections that accompany the spread of COVID-19 we may find it useful to explore several political hypotheses, which take us from globalization to its direct effects at home. Let’s try a few.

Washing hands (Photo: Fabio Fadeli)

The Sad Geopolitics of the Crisis 

Let’s start with the uncomfortable truth. While geared to prepare for war, the world is amazingly unprepared to fight viruses.

NATO, for example, has a rapid reaction force (NRF) which regularly carries out months’ long exercise programs in order to integrate and standardize all operational aspects – logistics, food and fuel provision, operational language, radio waves, etc. – across national contingents.

Nothing, nothing like that exists in the domain of health emergency and pandemic containment. The last serious simulation of a pandemic catastrophe in the US, the Dark Winter Exercise, took place in 2001. European countries are in even a worse condition. Europe doesn’t have a shred of a common health policy, so there is no joint program for tackling a health emergency. In addition, all of WHO emergency preparedness structures for identifying risks, issuing a global alert and coordinating immediate responses are, unlike NATO’s , short of funding and poorly-staffed. 

The unbelievable fact is that, while the first virus outbreak was wreaking havoc in Wuhan, European countries kept looking at China from a distance, and even with a certain degree of prejudice, cherishing the conviction that the epidemic would never really reach the Western world – no one seems to know why. Had government decision-makers seriously studied the data shared by China after WHO officially declared an international health emergency, they would have understood that the entire world was likely to have to deal with COVID-19 at different stages of the viral evolution. 

After several geopolitical slaloms and visible resistance, the WHO finally declared a COVID-19 pandemic on 11th March. Pandemic means sustained and continuous transmission of the disease, simultaneously in more than three different geographical regions. The threshold had been met, according to public health experts, weeks before the announcement.  The trajectory of the disease meant that the SARS-CoV2 virus had gained a foothold across the globe and multiplied quickly even in countries with relatively strong health systems.

While some analysts connect the WHO delay with the World Bank’s pandemic bonds mechanism, the highly due signal came in the end to rebuke and shake governments, mostly in the industrialized West, for their “alarming level of inaction”, in the words of the WHO Director General, Tedros Adhanom Ghebreyesus.  Whether because the pandemic can rattle markets and lead to more drastic travel and trade restrictions, or out of a dubious sense of political opportunism, a number of world leaders until very recently have either kept hiding or underrating the spreading capacity of COVID-19. In any case, they have delayed and still are delaying any serious containment measure. 

The WHO Director General’s preoccupation with the lack of cooperation among member states, voiced in late January on the eve of the  WHO Executive Board session (February 3-8), was  confirmed, two months into the global spread of COVID-19. Contrary to the obligations provided by the WHO International Health Regulations  (adopted in 2005, in the wake of the SARS epidemic to improve global capacity to prevent and control diseases), inter-governmental cooperation was rapidly supplanted by a viral health sovranism in dealing with the developing pandemic. That’s what we have seen happen in Europe, the cradle of the most violent COVID-19 outbreak, worldwide. Only a couple of weeks ago, most European countries were still indulging in inertia at home on how to face the disease, pretending that not much was happening. Buying time, somewhat in a state of denial.

Italy – the First Democratic Laboratory for COVID-19 Management

Donning the protective suit (Photo: Fabio Fadeli)

But time and trust are essential to good epidemic management. When Italy, the epicentre of the pandemic in Europe and the first democratic laboratory for COVID-19 management, asked for urgent medical supplies under a special European crisis mechanism, no European Union country responded. On the contrary, Germany, issued a decree to block exports of medical masks and other protective gear to Italian healthcare facilities. France, for its part, confiscated all available medical supplies by national order. Another slap in the face came from the European Central Bank (ECB) president Christine Lagarde, whose declaration implied that it was no longer ECB’s job to preserve Italy in the Euro zone. The result was the collapse of the Italian stock market, the loss of €68 billion of savings in one day, and the renewed kindling of financial malaise, alongside the viral. The impending question is whether Europe’s post-war institutional setup, grounded upon principles of solidarity and cooperation, will survive the COVID-19 pandemic.

COVID-19 is a groundbreaking test for European unity, a few weeks post Brexit. After the initial dormancy, draconian measures never before seen in peacetime Europe are forcing dramatic changes on daily life. More than 250 million people are in total or partial lockdown in the EU as Belgium and Germany have decided to follow Italy, Spain and France in closing schools and urging, or asking, people not to leave their homes. Only around mid-March, over two months after the Chinese declared their emergency outbreak in Wuhan (January 7th ), did Europe start to grasp the dimensions of the challenge. It took the European Central Bank heated internal debates before adopting a stimulus of €750 billion bond buybacks for the Eurozone to combat the economic and financial spillover unleashed by coronavirus. A much needed amount indeed, but still quite feeble if compared to Germany’s € 550 billion financial aid package and to the Trump administration’s US$ 2 trillion  stimulus to support the economy and the American families (9.5% of the national GDP). It has faced harsh criticism for its inactivity, but finally the European Commission found its footing and announced the suspension of the Stability Pact last week, much advocated for by the Italian government as coronavirus stretched the country’s defences, as well as Europe’s. Proposals asking for seizing this historical moment and launch new Covid19 credit lines, or very long maturity Eurobonds, are being voiced. Europe urgently needs a new catastrophe relief plan.  

“We’ll take the right steps, at the right time”, and “we can turn the tide of this disease in 12 weeks”, says Prime Minister Boris Johnson, with an apparent U turn from his initial – and quite controversial – strategy in the virus management. The UK government, which had sought to pursue business as usual, is moving towards more mass testing, social distancing and some school closures – shortly before Johnson himself confirmed that he had COVID-19.  

The SARS-CoV2 pandemic “could not have occurred at a worse time for the UK and its citizens” writes  Prof. Martin Mckee of the London School of Hygiene and Tropical Medicines, referring to the Brexit negotiations. Instead of doing everything possible to preserve the areas of relevant collaboration with the EU, such as health, “the UK has decided to isolate itself from European systems that have been built up over the past decade, many as a result of problems exposed by the 2009 swine flu pandemic“.  The country is now outside of the European Medicines Agency (EMA) rapid authorization mechanism for pandemic vaccines and medicines, which entails that the UK has to wait longer for these health tools then the EU member states. To worsen the picture, the UK has also withdrawn from the EU’s emergency bulk purchase mechanism for vaccines and medicines. This lever allows EU governments to enhance their market power and speed up access to vaccines and medicines during an emergency situation.  

Ultimately, as humans we are a limitless pastureland for the virus but we are, above all, a very disordered, unprepared, and yet arrogant herd. The result is considerable governance failure so far, while the WHO Director General implores us: “do not let the fire burn”. More of this is to be seen if we open a broader view beyond the borders of Europe.  What will happen, now that SARS-CoV2 creeps steadily into most African countries? The geopolitical implications may not come secondary to matters of health and safety.

Selfie in full protective gear.

Tension between Health and the Economy 

One of the reasons why the right to health is subject to so many violations lies in the fact that health cannot live in isolation. The right to health drags along with it other social and economic rights, which exist in a constant friction with economic rules and financial profits. On the other hand, disease spread implies economic losses. That’s what makes health and the economy so intertwined. With astonishing foresight, 2019 report of the World Bank Global Preparedness Monitoring Board pointed out the “very real threat of a rapidly moving, highly lethal pandemic of a respiratory pathogen” which could wipe out nearly 5% of the world’s economy. Now, with the coronavirus outbreak a reality, the OECD has warned that it could halve global economic growth this year to 1.5%, the slowest rate since 2009. It has cut its 2020 growth forecast for China to a 30-year low of 4.9%, down from 5.7% in November. Even as China slowly goes back to work, the virus continues to cause massive economic disruption. The virtual shutdown of China’s ‘factory of the world’,  decreased the supply of products and spare parts, disrupting production the world over. Low and middle income countries, especially those dependent on commodity exports and global supply chains, are particularly vulnerable in this economic havoc.

In Italy, we have been confronted far too many times over the past years with the dilemma between health and the economy (and employment) across the country. These same tensions led to the flagrant missteps in the country’s early management of COVID-19S, particularly at the regional level. No need to lecture: things are complex, and policy decisions not easy. Yet, right from the start, the highly productive valleys of Lombardy got engaged in arm wrestling with local entrepreneurs over the need to recognize and curb the contagion with rigorous public health measures and resistance to a contraction in economic activity that a health lockdown would create. Local authorities hesitated, as the contagion kept surging, and central government likewise fluctuated at the end of February. After initial containment measures, contradictory messages aimed to reassure the North’s economic exuberance (“Milano non si ferma”, Milan doesn’t stop), ended up legitimizing baseless patterns of behaviour that favoured the virus spread. 

Two different strategic approaches in tackling COVID-19 may be identified so far: Firstly, there is combat of virus spread through mass testing and social distancing measures, including the extraordinary forced isolation of communities in the Chinese and Italian model. Secondly, and arguably the flimsier approach to the contagion, places an exclusive focus on testing and treating the most affected people (the English, German, Dutch and partly French model). Of course, the containment option entails economic costs but, as Roberto Buffagni highlights, it is rooted in the legacy of ancient cultural and political values that apparently keep inspiring the decision-making style in those countries, if only by instinct.

On the other hand the laissez faire strategy, still the norm in some parts of Europe, has its roots in a pragmatic analysis which bears some sinister social selection implications. In the case of COVID-19, the more at-risk population is largely made up of elderly people, or people with other forms of chronic disease. Their loss, however painful, does not pose a threat to the functionality of the economic system, the laissez-faire theory goes. Rather the reverse. In fact, it operates with somewhat re-generational leverage, insofar as it alleviates the pension system costs alongside the costs of other social welfare structures in the country. The resulting dynamic therefore triggers off an economically expansive process “due to the legacies that, as in the great past epidemics, will enhance the liquidity and assets capacity of new generations who have a higher inclination to investments and consumption than their elders”, says Roberto Buffagni. By so doing, a government increases its economic and political operability, when compared to countries that choose the costly lockdown route. 

However, as Italians know only too well now, another critical element in the policy puzzle in either scenario, is the functionality of the health system in terms of its ability to prevent disease, treat and manage those who become ill.  And when health services are overwhelemed, an unchecked viral outbreak will ultimately lead to massive economic deaths, a toll linked also to the exasperating epidemic of precarious labour conditions, even in highly successful national economic sectors like tourism. COVID-19 has thus brought to the surface the many hidden pathologies lingering in the economic fabric of the country, untreated for too long. If the virus marks a watershed in our history, and in the history of Europe as a whole, we need to go beyond the immediate COVID-19 emergency response to advance the urgent political and economic regeneration we have long wanted to see. It’s time to work for a systemic reframing of our attitudes about health systems and services, in a post-virus world, to prompt positive changes in line with our constitutional rights. 

Health as a Common Good & the Role of the Public Health System  

We needed the SARS-CoV2 shockwave to convince Italian public opinion about the value of the national health system (Servizio Sanitario Nazionale,1978), as the main tool that secures communities and grants individuals protection from catastrophic life events. After two world wars, national health systems were gradually introduced in Europe as the most effective institutional mechanisms for sealing societies’ democratic pacts.

In Italy, the universal public health system has been instrumental in the social and economic development of the country and still today accounts for its high population life expectancy, according to Bloomberg.  The renewed awareness of the difference that a universal, free public health institution can make, is vividly present in the hardest hit countries now. Initiatives such as Spain’s to place all private hospitals under state control indefinitely should spread internationally like the virus, and generate a strong global consensus around a rights-based vision of health systems and services, which goes beyond issues of financial resources. I consider it the political point-of-no-return of the current viral crisis. In fact, this is the coronavirtue that we must seize and preserve, if we are serious about universal health coverage and sustainable development for all. 

In the name of neoliberal ideologies, and often in the name of odious debt service repayment, the development of solid health systems in the global South has been stubbornly opposed for decades, with a huge toll in the health and lives of billions of people. Most low and middle income countries are therefore now facing the coronavirus bare-handed. Years of spending cuts due to fiscal austerity policies also have undermined public health provisioning in developed economies, so that health systems have been dismantled and broken to pieces in Europe, as well. As for Italy, debt reduction and spending reviews have shrunk investments – health expenditure increased by 14.8% from 2001 to 2008, by a meagre 0.6% from 2009 to 2017.  

Despite the aging of Italian society, the national health budget  was trimmed by €25 billion between 2010 and 2012, local health units were dismantled (contracting from 642 in the 1980s to 101 in 2017), and 175 hospitals were closed down. Repeated rounds of devolution and privatization have dismembered the Italian national health system to the advantage of private insurance schemes.  Nowhere has this trend of public health system dismemberment been more apparent than in Lombardy, which has been the hardest hit by the pandemic, despite being the wealthiest region of the country.

The compelling title of the 2018 Censis-Rbm reportResentment Healthcare, Resentment for Healthcare: Scenes from an Unequal Country – illustrates the disquieting portrait of an out of control “out-of-pocket-society”. Private spending on health services increased by 9.6% from 2013 to 2017, forcing over 7 million people into debt, or into selling their properties (2.8 million people) to access their right to healthcare.  A perfect crime against common sense. Confronted with SARS-CoV2, Italy has today less than half the number of intensive care beds than Germany, or France. 

Building on Covid19’s Lessons: Policies for the Future

Health workers in Lecco, Lombardy, Italy in full protective gear.

The devastation is under our eyes. Italy’s death toll has overtaken China, with 4% of China’s population. The immediate reduction of the virus spread is no doubt the most urgent priority now to avoid the collapse of the health system, with all its implications. 

At the same time, we need to start planning now for the necessary policy changes that should be undertaken post-emergency, across the social and economic spectrum. Health-wise, more adequate financial and human resources will have to be injected into the universal health system. We need to undo the damage caused to public services in the past and we need to revise the balance of power and the rules of engagement for the private sector, including in the area of scientific and medical research. There are no reasons why health should be allowed to assert itself as a profit-extracting mechanism. 

A new governance for health will have to be set in place in Italy. National Health Services means national, i.e. centralized, and not splintered into a variety of regional strategies more or less ancillary to the temptations of the private sector. Health devolution, introduced in 2001, has not functioned. Overall, it has resulted in significant health inequalities. 

A Mirror To The World

On a small scale, Italy mirrors the health divide existing between the North and the South of the world. It has produced different and diverging approaches, multiplying inefficiencies and opportunities for corruption (in line with the global empirical evidence), and ultimately increasing costs. 

As the early stages of the virus outbreak have clearly demonstrated, health devolution responds very poorly to the complexities involved in the production of good health. That is why we need to definitively reverse those national policies that currently tolerate regimes of “differentiated autonomy”, especially in Italy’s northern economic powerhouses (Lombardy and Veneto). 

Italy is thriving in emergency conditions, for a series of structural reasons. We have the second oldest population in the world after Japan – possibly, the main cause of COVID-19 higher mortality rate in Italy. The country is the hardest hit by climate change in Europe, both for its geographical position and geographic conformation. Above all, Italy bears already a number of serious health crises that need more adequate national  policies. Antimicrobial resistance (AMR) is one good example. We are the EU country hosting the highest number incidents of antimicrobial-resistant infections. According to the European Centre for Disease Control (ECDC) and the Istituto Superiore di Sanità (ISS), Italy alone accounts for one third of all the AMR-related deaths in Europe.  Renowned virologist Ilaria Capua has aleady hinted at the potential relationship between these higher levels of AMR and higher SARS-CoV2 mortality in the country. 

Post COVID-19 will be like post-war, with its unpalatable numbers of victims, its rubble, and the need for reconstruction. Nothing will be the same anymore. But new conditions are emerging, a new historic awareness is spreading. This calls upon policymakers to redesign a stronger and better country. A stronger and better Europe. In its tragic manifestation, silent and intrusive Coronavirus is paradoxically our best chance. 

_______________________________

Nicoletta Dentico

Nicoletta Dentico is a journalist and a senior policy analyst, leading the Global Health programme of the Society for International Development (SID, www.sidint.net). She previously was director of Médecins Sans Frontières (MSF) in Italy, and she has also played an active role in the MSF campaign on access to essential medicines as well as consulting for the World Health Organization. 

Image Credits: (Fabio Fadeli).

Carlos Alvarado Quesada, President of Costa Rica

World Health Organization Director General, Dr Tedros Adhanom Ghebreyesus has welcomed the call by Costa Rica’s President, Carlos Alvarado Quesada, for WHO to launch an initiative that would “pool rights to technologies that are useful for the detection, prevention, control and treatment of the COVID-19 pandemic.”

“I welcome his initiative & call for pooled rights to COVID-19 diagnostics, drugs & vaccines, said the WHO Director General in a reply Thursday on his Twitter account to the presidential overture. “WHO is working closely with governments & agencies around the world to promote rapid R&D. These efforts are rooted in our commitment to equitable access for all.”

Alvarado’s letter, dated Monday 23 and co-signed by Costa Rica’s Health Minister, Daniel Salas, also called for the creation of a “repository of information on diagnostic tests, devices, medication or vaccines, with free access or licensing on reasonable and affordable terms, in all member countries of the Organization,” according to excerpts later posted on the presidential website and Twitter account.

Meanwhile, in another letter to the WHO Director General dated 25 March, the WHO hosted-partnership UNITAID,  offered to work with WHO and the Medicines Patent Pool, a public-private partnership that it founded, to identify “concrete steps to ensure that there will be equitable and timely access to critical health technologies and products for COVID-19 for people anywhere in the world.”

“We appreciate that several initiatives are underway or proposed that seek to address access barriers; this includes but is not limited to the proposal that has been sent to you by the President of Costa Rica about a voluntary pool of patents for COVID-19 related medicines and technology,” the UNITAID letter added.

In his letter, the Costa Rican president further urges the WHO to “develop a memorandum of understanding to share this technology, and to promote its implementation with financial support from the public and private sectors, as well as from international organizations.”

The president also asked WHO’s Global Observatory on Health Research and Development create a database on research and development activities related to COVID-19, including estimates of the costs of clinical trials and subsidies provided by governments and charities.

Extraordinary Virtual Summit of G-20 Leaders Pledges Massive Support for Global Health Response   

Meanwhile, in an Extraordinary G20 Leaders’ Summit on COVID-19, the Group of 20 most industrialized nations issued a far-reaching  set of commitments to fight the pandemic on health, economic and social fronts. Among their key health-related commitments, leaders pledged to protect the most vulnerable as well as safeguarding the global economy; expand manufacturing capacity to ensure medicines and supplies would be available widely at an affordable price; and support WHO and other global health institutions.

“We commit to take all necessary health measures and seek to ensure adequate financing to contain the pandemic and protect people, especially the most vulnerable,” the G-20 statement said at the close of a virtual one-day meeting on Thursday. “We will share timely and transparent information; exchange epidemiological and clinical data; share materials necessary for research and development; and strengthen health systems globally, including through supporting the full implementation of the WHO International Health Regulations (IHR 2005).

“We will expand manufacturing capacity to meet the increasing needs for medical supplies and ensure these are made widely available, at an affordable price, on an equitable basis, where they are most needed and as quickly as possible.”

As for support to WHO and other global health preparedness and R&D efforts, the G-20 statement said: “We will quickly work together and with stakeholders to close the financing gap in the WHO Strategic Preparedness and Response Plan. We further commit to provide immediate resources to the WHO’s COVID-19 Solidarity Response Fund, the Coalition for Epidemic Preparedness and Innovation (CEPI) and Gavi, the Vaccine Alliance, on a voluntary basis. We call upon all countries, international organizations, the private sector, philanthropies, and individuals to contribute to these efforts,”

While acknowledging the need for “urgent short-term actions” to protect front-line health workers, deliver medical supplies, diagnostics tools, medicines and vaccines, the statement also acknowledged that deeper structural changes are needed to bolster health systems, emergency preparedness strategies and spending, as well as related R&D.

“To safeguard the future, we commit to strengthen national, regional, and global capacities to respond to potential infectious disease outbreaks by substantially increasing our epidemic  preparedness spending. This will enhance the protection of everyone, especially vulnerable groups that are disproportionately affected by infectious diseases. We further commit to work together to increase research and development funding for vaccines and medicines, leverage digital technologies, and strengthen scientific international cooperation.

“We will bolster our coordination, including with the private sector, towards rapid development, manufacturing and distribution of diagnostics, antiviral medicines, and vaccines, adhering to the objectives of efficacy, safety, equity, accessibility, and affordability,” the statement added. “We ask the WHO, in cooperation with relevant organizations, to assess gaps in pandemic preparedness and report to a joint meeting of Finance and Health Ministers in the coming months, with a view to establish a global initiative on pandemic preparedness and response. This initiative will capitalize on existing programs to align priorities in global preparedness and act as a universal, efficient, sustained funding and coordination platform to accelerate the development and delivery of vaccines, diagnostics and treatments.”

In his speech at the G20 Extraordinary Leaders’ Summit on COVID-19, Dr. Tedros welcomed G20 leaders promise to “do whatever it takes to overcome the pandemic”.

“This is a global crisis that requires a global response”, he said, adding that leaders need to. “Fight, unite, ignite… with no excuses and no regrets.”

“”No country can solve this crisis alone,” he said, calling upon countries to build upon the solidarity that has so far been expressed, and exhorting them to “ignite a global movement to ensure this never happens again. “

Britain Announces £210 Million to COVID-19 Vaccine Effort 

Also today, the United Kingdom announced that it would provide some $US 254 million (£210 million) in new funding to the Oslo-based Coalition for Epidemic Preparedness Initiative (CEPI) to support the quest for rapid development of a vaccine for COVID-19, in what represents the single largest commitment so far to vaccine research.

CEPI CEO, Richard Hatchett, said the financial support “comes at a pivotal moment for a world that is in crisis. The UK has a long history of global health leadership and, today, the UK is once again stepping up as a global leader in its support CEPI and our crucial work to accelerate the development of a vaccine against COVID-19.”

The UK contribution complements pledges that have already been made by Germany, Norway, Denmark, and Finland, Hatchett said, noting it brings CEPI “closer to the $2 billion we urgently need develop a COVID-19 vaccine and we call on other world leaders to join us in our fight.”

Jeremy Farrar, Director of Wellcome Trust, welcomed the UK government pledge in a statement saying: “Support from enlightened Governments, with commitment to the global research effort is vital if we are to end this pandemic and prevent future tragedies. The pace and impact of the spread of this virus is unprecedented, our global response must be too. The research effort to rapidly advance the vaccines, treatments and diagnostics needed to save lives has been nothing short of staggering. Global support is still, however, falling seriously short – by at least $8 billion in the short-term.

US Appears Set To Overtake Italy as New Epicentre of COVID-19 Emergency 

Active cases around the world as of 2059PM CET 26 March. Right column shows cumulative case count. Numbers are rapidly changing.

The announcement of new investments in emergency response came as the United States appeared set to overtake Italy as the new centre of the COVID-19 pandemic.

There were now 521 086 reported cases of the virus worldwide, nearly 61 000 new cases since yesterday. Of all WHO regions, the European Region continued to experience the largest increase in new cases, with more than 25,000 fresh reports over the past 24 hours, ccording to WHO’s  daily Situation Report, followed by the Americas, with 11,390 new cases, and the Eastern Mediterranean region, with 2,416 new cases. In Europe, Spain is currently experiencing the highest growth in cases, having risen by approximately 10 000 cases since yesterday. In the Eastern Mediterranean region, Iran saw over 2,234 new cases. 

India Converting Railway Coaches to Hospitals 

In South-East Asia, where there were now 2344 cases, and Africa, which now had 1664 confirmed reports, government leaders were moving evermore aggressively on pre-emptive measures – while facing large, looming gaps in available hospital beds, medical supplies and services.

On Wednesday, India began a 21-day, nationwide lockdown along with announcing a massive aid bill to support its citizens during the closure. The bill aims to provide rice/lentils for ~60% of the country’s 1.3 billion people.  “No doubt this lockdown will entail an economic cost for the country, but saving the life of each and every Indian is the first priority for me,” said the Indian Prime Minister Narendra Modi, “If we are not able to manage the next 21 days, then many families will be destroyed forever. 

Mathematical modelling suggests that 300 million Indians could become infected by COVID-19, of which about four to five million could be severe, said Dr Ramanan Laxminarayan, director of the Center for Disease Dynamics, Economics and Policy, in an interview with the BBC. 

India’s dense population, which is one of the main drivers for India’s high predictions,  has not made it easy – Last wednesday, the first case of COVID-19 was reported in a slum of Mumbai inhabiting over 23,000 people in less than a square kilometre of land. Contact tracing has proved particularly difficult. 

In an attempt to alleviate an overwhelming shortage of beds in India and to prepare for a growth in COVID-19 cases, India was looking to convert its trains into hospitals.

Given that railway services in India have been suspended and the ready availability of 12 617 trains, with 24-30 coaches in each train, 10 million beds can be created “within no time”, said Sunil Kumar V, Managing Director of Asset Homes to to the Prime Minister and the authorities of the National Disaster Management Authority.

As of last Sunday, Indian National Railways had begun moving coaches to their home zones so as to prepare them for disinfection and quarantine facilities.  Meanwhile, the Indian government has said that all scheduled international commercial passenger flight services would remain closed till April 14th. 

Four fifths of countries in Africa are not Adequately Prepared for COVID-19

WHO Regional Director for Africa, Matshidiso Moeti, meanwhile said that local virus transmission still was not widespread on the continent, but time was running out to prepare.

“We still have a window of time that is narrowing. In about half of countries, we still only have imported cases. We have not yet identified that local spread is occuring,” she said, speaking at a World Economic Forum webinar on Thursday. 

She said that the draconian border closures that have been undertaken now in many African nations need to be accompanied by stronger public health interventions, including more systematic identification of cases, follow-up of contacts, and isolation of cases and contacts, as needed.

While some countries like Spain have already recommended the anti-malarial chloroquine to treat COVID-19 as part of their national outbreak response, Africa is “waiting to get robust data [from the WHO’s multi-country clinical trials] to make recommendations [about using chloroquine], said Michel Yao, Emergency Operations Programme Manager at the WHO’s Regional Office in Africa. 

“If clinical trials show the potential of the drug, we should use it. We will not recommend it formally before its impact and side effects are properly measured”, he said in the webinar. 

Only about a fifth of African countries (8/47) are adequately prepared to response, according to a WHO African Region Readiness Response Sheet. These include Algeria, Ghana, Cameroon, Kenya, Tanzania, Madagascar and Ethiopia. Another 33 countries are moderately prepared, while 7/47 countries have limited readiness status, including Benin, Namibia, Guinea Bissau and Gambia.

Among the issues identified, the assessment found that:

  • Only a quarter of African countries have full access to PCR test materials for the SARS-Cov-2 virus;  while 39/48 countries have the capacity to detect viral pathogens using an open-PCR platform, only 12/48 have access to primers (probes) specifically designed to detect SARS-Cov-2 using PCR assays.
  • Only 7/48 African countries have benefited from health worker training on Covid-19 (Angola, Botswana, Eswatini, Ethiopia, Ghana, Lesotho, Seychelles), and only 4/44 countries have districts with health facilities that benefited from training on detection and reporting on Covid-19. These include Seychelles (100), Lesotho (70), Zanzibar (36), Liberia (4);
  • There are only 9 countries in the whole African continent that have more than 50 facilities with nCoV case definition and surveillance tools, including: Algeria (100), Capo Verde (100), Cote D’ivoire (100), Mauritius (100), Seychelles (100), Togo (100), Rwanda (100) Senegal (54), Gambia(51);

However, African countries seemed better prepared in terms of biosafety, the assessment found. Some 45 countries out of 48 had stocks of personal protective equipment (PPE), although only about 30 countries have sufficient PPE for medical staff for case management and screening procedures. Some 44/48 countries reported that air and transport distribution systems are available in the country to restock supplies. 

-Svet Lustig, Tsering Llhamo and Zixuan Yang contributed to this story.


Warning: Attempt to read property "post_title" on null in /home/clients/58f2a29976672af522a8f4d82ffa28b6/web/wp-content/plugins/better-image-credits/better-image-credits.php on line 227
Medellin, Colombia’s Parque de las Luces stands empty on bank holiday after city and regional leaders call on the population to stay indoors due to COVID-19 threat.

In normal times, Diego Zapata, undersecretary in the City of Medellin’s Mobility Department, worries about how to advance better public transit systems, cycling and pedestrian networks – to get more people moving around the city.

But recently, he and his boss Carlos Cadena began supporting the City’s Health Department in its scramble to reduce travel around the city – and scale up capacity to rapidly diagnose new COVID-19 cases so that Colombia’s second largest city can head off a wider, and more devastating outbreak of the novel coronavirus. 

The disease is just now beginning to gain a foothold in Latin America and Africa.  As of Tuesday, some 52 people in the Medellin metropolitan region and 378 Colombians nationally had been reported ill. 

Just a week ago, tests for COVID-19 could only be done in the national laboratory in Bogota, leading to considerable delays and limiting local test capacity. But on Friday, a breakthrough occurred – the Antioquia Regional Laboratory in Medellin also began conducting tests, after training staff and securing precious reagents. 

“There is an urgent need to improve regional and local testing capacity to try to contain the pandemic”, says Zapata last week, in an interview with Health Policy Watch. As a clean air and mobility advocate, he has been particularly worried that Medellin’s population, includes many older people and migrants, who have suffered a period of chronic exposure to heavy air pollution emitted by forest fires in Colombia’s northern region, could be particularly vulnerable to the impacts of the virus on respiratory health.

Diego Zapata at work in normal times promoting clean, sustainable transport for Medellin, Colombia.

Such concerns reflect the “whole of government” approach that some lesser-affected cities and regions in Africa and Latin America are now putting in place to get ahead of the virus wave, as well as the steady global uptake of a key message issued by WHO’s Director General Dr Tedros Adhanom Ghebreyesus, who told the world last week that expanded use of diagnostics is key to fighting the outbreak: 

“Test, test, test. You cannot fight a fire blindfolded. And we cannot stop this pandemic if we don’t know who is infected,” said Dr Tedros.   

That message was underlined again on Sunday by WHO’s Emergency Head Mike Ryan. He told the BBC’s Andrew Marr that the lockdown measures being widely used in Europe and elsewhere are not enough on their own to solve the crisis. Such restrictions in Asia only succeeded because they were also accompanied by rigorous testing – “once we’ve suppressed the transmission, we have to go after the virus,” he said.   

Indeed, while some countries and cities have appeared almost lethargic about testing, other countries, regions and cities are racing to find new and creative ways to activate testing and other local measures, with any available resources.  

The challenges and opportunities cut across economic and geographic fault lines – from high-income Europe, the new virus epicentre, to North America and low- and middle-income countries of Africa and Latin America. Regional and local laboratories like Medellin’s, which sprawls across a metropolitan area of nearly 4 million people, are gearing up, and new rapid tests are just coming online, offering hope that more and more cities and regions in low- and middle-income areas can accelerate testing capacity.  

Early on in the epidemic, however, Asia created some good practice examples for how diagnostics can be wielded to stem the tide of new cases – in the context of broader public health strategies. And Africa is eyeing the development of rapid COVID-19 test technologies – which have contributed so much in turning the tide on infectious diseases such as malaria and HIV/AIDs.    

Health Policy Watch (HPW) looks at the diagnostics landscape through the lens of these Asian stories of success, as well as the promising new innovations such as rapid diagnostics now on the horizon – while recognizing that there is no “one-size-fits all” approach.  

(HPW/Svet Lustig): How countries rank in COVID-19 tests/per million population. Developed from national test data collected by FIND (finddx.org) as of 24 March, 2020.

The Republic of Korea: Tested Like Mad – No Nationwide Lockdown Imposed 

Any story on diagnostics has to begin with the Republic of Korea, founder of the now legendary “drive-in” test sites, and the country outside of China with the largest COVID-19 test capacity in the world – with 6,471 people tested per million, or about 15,000 tests per day. 

Korea’s decisive measures centered on widespread testing, transparency and education have helped slow down the outbreak and minimize panic amongst civilians.

Schools and kindergartens closed, and mass events were cancelled. The southeastern cities of Cheongdo and Daegu, and parts of North Gyeongsang province as “special disaster zones”. But thanks to its aggressive testing and contact tracing early on, Korea largely avoided the kinds of massive commercial shutdowns and widespread restrictions on individual movement that are now being seen in Europe and North America.  

(HPW/Svet Lustig): COVID-19 test trends in selected low- and middle-income countries of WHO’s Western Pacific (WPRO), Eastern Mediterranean (EMRO) and Americas (AMRO) regions. Developed from national test data collected by FIND (finddx.org) as of 24 March, 2020.

 

(HPW/Svet Lustig): COVID-19 test trends in selected countries of WHO’s European Region. Developed from national test data collected by FIND (finddx.org) as of 24 March, 2020.

The integrated strategy also helped keep mortality rates down. Death due to Covid-19 in Korea have so far been three times less than the global average

“It’s much better to test and then quarantine a specific person than to do a city-wide or province-wide lockdown, which in certain ways prevents the virus from leaving the province but actually doesn’t make the province any less likely to have high infection rates,” says Dr.Eric Feigl-Ding, a senior fellow at the Federation of American Scientists in Washington, D.C., and an epidemiologist at the Harvard Chan School of Public Health.

A Network Approach to Laboratory Response

With the memories of the 2015 outbreak of Middle-East Respiratory Syndrome (MERS), which killed some 38 Koreans, fresh in mind, the country already had undertaken key reforms to allow quick approval of new diagnostics during emergencies, maintain local production capacity, and link public and private labs together in a national network. 

This allowed Korean manufacturers to design and create a COVID-19 test, as well as get a network of 96 labs across the country to work on manufacturing and using it, within 17 days, Professor Gye Cheol Kwon, the chairman of the Laboratory Medicine Foundation, told the BBC. The organized network function also helped avoid the inconsistencies in test quality, production rates and distribution, seen in other countries.

Inspectors visit a drive-in COVID-19 test site in Busan, Republic of Korea

Test Strategy Cast a Dragnet

With plenty of tests available across the country, thanks to the well-organized laboratory network, Korea focused its very first rounds of testing around the contacts of the first clusters of COVID-19 infections emerging among travelers returning from abroad as well testing all 210,000 members of the cult-like Shincheonji church in the southeastern city of Daegu as well as North Gyeongsang province, where the first virus clusters had emerged. 

Much broader criteria were soon adopted; these enabled anyone with a simple doctor’s note to get a free test. Those lacking a note could still get a test for US$130. Any subsequent  hospitalization and treatment were also offered for free – further incentivizing people to get the tests without fear of debilitating health care costs. This contrasts sharply with the approaches that are now being taken in some European countries, such as France and Switzerland, where decisions on testing remain in the hands of health care providers and only people deemed to be highly symptomatic or at high risk are allowed to be tested at all.  

A hallmark of Korea’s Covid-19 response has been their drive-thru testing centres. The procedure takes approximately 10 minutes, and is able to test 10 people per hour, which is twice as fast as diagnosis in an indoor clinic. Briefly, drivers are asked to answer a short questionnaire, their temperature is taken and they are swabbed inside their nose. This approach has been shown to be convenient and safe, especially for front-line workers and patients in waiting rooms, limiting the potential for the virus to spread. 

In densely populated city centers, where vehicles are less common, Korea also implemented mobile testing stations and staged home visits, which allowed for the identification of positive cases within hours. 

Testing Part of Integrated Strategy 

The government has also promoted social distancing, encouraging the roll-out of church services online in the devout population. The government also invested heavily in digital and social media outreach, including personalized mobile phone messages complementing 2x daily public press briefings. 

Creative uses of digital technologies also played a role. The government used private civilian phone data to anonymously track positive cases by GPS location. Applications, such as Corona100m, also used such publicly-available data to help civilians avoid high-risk areas linked to the Covid-19 outbreak in a user-friendly fashion, even as they moved about freely, in most cases. 

Via Corona100m, users received phone alerts if their proximity to any recorded case was less than 100 meters. The phone app was downloaded 1 million times within 10 days of its launch. Although the information is ‘anonymized’, concerns also arose, however, about privacy infringements.  

Instead of shutting down airports completely, Korea last week adopted additional screening and mandatory quarantine measures, for all Koreans as well as foreign nationals into the country.  This also helped mitigate Covid’s impacts on the economy. 

From its precarious ranking as the largest cluster of cases outside China in mid February, Korea this week had 5884 active cases, and was reporting only about 94 new cases a day on average, last week.

“We must maintain this trend. We have come this far thanks to the citizens who were united and cooperated well with the government. But it’s too early to be optimistic. Please be a little bit more patient and stay away from mass gatherings such as religious events. Moon Jae-in, Korea’s president, told The Guardian recently.

“South Korea showed to the world that it can allow curtailing a pandemic with limited infringements to individual freedom and disruption to the economy and the fabric of society,” Dr. Balloux wrote.

Singapore: Public Health Preparedness Clinics Take Load Off Mainstream Health Services 

Singapore light rail lines continued to operate at height of COVID-19 emergency. Source: Jade Lee.

Singapore was one of the first countries outside of China to be hit by Covid-19, and had the highest number of cases outside of China for almost two weeks in February 2020 (05/02/2020-18/02/2020). It’s successes in “flattening the curve” since have made it the country with the slowest Covid-19 growth rates in the world (doubling time of 7 days).  

“Test, test test”  was also a cornerstone of the city-state’s policy from the beginning – including broad criteria for who should get a test, free testing, and diligent tracing of contacts of confirmed cases.  

While Korea created drive-in test sites, a hallmark of Singapore’s outbreak response was the re-activation of its Pandemic Preparedness Clinics, used in the H1N1 flu era and in air pollution haze events, to administer tests and provide follow-up. 

Rebranded as “Public Health Preparedness Clinics,” the 900 PHPCs offer COVID-19 tests to the public in venues separated from mainstream health services, protecting patients and health workers alike. 

The Ministry of Health recommends any patient with respiratory symptoms, fever, cough, sore throat and runny nose seek help at PHCPs, which are mandated to not only test, but also dispense initial treatments, and conduct follow-up investigations. As an additional precaution to ensure that no potential case remained unidentified, Singapore’s health authorities also mandated private doctors to test any patient with flu or pneumonia-like symptoms. 

Ramping up Local Diagnostics Capacity .

Even before COVID-19 first hit Singapore on February 23 2020, diagnostics were also widely accessible. Within a week of Covid-19’s sequencing by Chinese scientists (12 January 2020), the Multi-Ministry Taskforce coordinating COVID-19 response had done the necessary legwork to organize local manufacture of large quantities of diagnostic tests.

As of 25 March, the widely available and free testing (with a doctor’s note) had helped identify a total of 8930 close contacts of known virus cases. All such contacts, as well as travelers arriving from elsewhere, are quarantined for 14 days. Of the contacts, 6287 have completed their quarantine and 2643 are still under quarantine. But other Singaporeans can move about freely.  An antibody blood test was also used to help investigators track down the source of the original large outbreak, which was linked to a church group, STAT News reported.  

Modest (yet effective) Social Distancing measures 

Dorcson alert levels. Source: Singapore Ministry of Health.

While Singapore has social distancing measures, the approach stands in stark contrast to the much stricter measures adopted in Europe or the ‘shelter-in place’ orders in USA hotspots. 

Schools remain open, although children’s temperatures are screened prior to entry. Singapore reduced the scale of public events to below 250 participants, which is still far less restrictive than recent measures seen in Europe. To protect the elderly, all “senior-centric activities” are suspended until the beginning of April.

While the Ministry of Health has previously said that risks to the public “from transient contact, such as in public places, is low,” last week it issued stricter advice to reduce frequency of get-togethers and socializing. 

“Social responsibility is a critical factor in slowing the transmission of the virus. We need all Singaporeans to play their part in the fight against COVID-19…This means reducing the frequency of [get-togethers], and minimising physical contact with one another. Those who are unwell, even with mild flu-like symptoms, should see a doctor and stay at home to prevent spreading illness to others.”, stated the Ministry of Health of Singapore in a press release.

Singaporeans have expressed strong support for the government’s early and aggressive testing measures. 

Full faith in the medical personnel of Singapore,” wrote one Singaporean, Joyce Chan, who went to the doctor for a simple cough and wound up getting a COVID-19 test.  

“With such dedicated medical professionals and good systems and processes in place, I have full confidence that Singapore can handle this situation well. Now, more than ever, is the time to seek treatment if you are feeling unwell (instead of potentially passing any virus on to others)….The experience gave me 100% confidence in Singapore’s preparedness to contain and deal with the current #Covid19 situation”, said Chan, who agreed to be quoted by Health Policy Watch.

SARS was a Template for Singapore Response 

The residual traumas of the SARS epidemic of 2003, as well as the H1N1 crisis of 2009, were etched into collective memories and that helped spur Sinaporeans to rapid, collective action, observes local journalist Jade Lee. 

“Singapore was hit by SARS in 2003, and that gave Singapore a template for response,” she said. “It was the lived experience that made Singapore much more cautious early on. We had the advantage of moving fast and aggressively against the virus from the beginning.”

Efficient governance also helps. 

Singapore is a good example of an all-of-government approach – Prime Minister Lee Hsien Loong’s regular videos are helping to explain the risks and reassure people”, said  Dr Tedros Adhanom Ghebreyesus, Director-General of the World Health Organization in a press briefing on Covid-19.

As Dale Fisher, professor at the National University of Singapore, noted in an interview with The Guardian: “We [Singapore] don’t do anything different, we just do it well.”

Gearing Up in Africa – GeneXpert and Rapid Diagnostic Tests  

A scientist at Ethiopia’s National Influenza and Arbovirus Laboratory, equipped to test for COVID-19.

Right after an international public health emergency was declared, WHO launched a massive drive to equip African health systems, deemed to be the most vulnerable,  with tools to test and treat patients.  

In early February, WHO shipped over 200,000 tests to 47 countries across the continent and trained national labs or central hospitals in 40 countries to process test results. 

Paradoxically, the virus headed north instead, over ever widening swathes of Asia, Europe, The Middle East, and North America, while Africa was largely spared. 

Now, however, as Africa begins to see its first real wave of cases, those initial tests are rapidly being used up, notes Owen Kaluwa, WHO Representative for South Africa, which received just 2,500. 

“There were 200,000 kits for the 47 countries that our offices are covering,” he said at a WHO Africa Region Office press briefing last week. “This is what they started with and what they are using now, most are requesting replenishment, as they are seeing increasing numbers of cases. 

In light of the greater infectious potential of the virus, and sheer numbers of people becoming ill elsewhere, African health authorities are hoping to see the expedited development of rapid diagnostics tests – which played such a large role in combating other diseases like HIV/AIDs and malaria.  

Speaking at the press briefing on 19 March, Matshidiso Moeti, WHO Regional Director for Africa, said that African nations want tolearn from the experiences of other countries which have seen a sharp decline in COVID-19 cases through rapidly scaling up testing, isolating cases and meticulously tracking contacts.”

Owen Kaluwa, WHO/South Africa (left); Dr. Matshidiso Moeti, WHO Africa Regional Director (center)

But she added that Africa would need more low-cost and rapid test solutions to be effective. 

“As regards the test kits and the global challenges in their availability.. we would like to encourage a very focused screening and case finding strategy where those who have symptoms and their close contacts would be tested, and that would allow us to initiate the measures around social distancing, hygiene, isolation that are so important,” Moeti said.

“We are aware that there is a challenge. But we are very keen to explore test kits and testing approaches that will be carried out in a minimally demanding way, and as broadly as possible, before or right when people start showing symptoms”, Moeti said.

According to FIND, the Geneva-based non-profit public-private diagnostics partnership, there are already nearly 100 some rapid tests, mainly antibody blood tests, already commercialized in China and the Republic of Korea, and elsewhere in Asia. 

In the USA, the first antibody blood test, developed by Mount Sinai’s Icahn School of Medicine, was now due to be piloted soon in the USA COVID-19 epicentre of New York City. The test can also identify who has been exposed to the virus and may be immune or asymptomatic. 

The US FDA has agreed that body-fluid tests can be marketed with an abridged process of agency review. 

Other such tests are also under development in Europe, North America and elsewhere. But none so far have received a WHO, European or US regulatory seal of approval to a level that would pave the way for bulk, donor-funded purchases and use in clinics and field settings, such as Africa. 

The UK-based firm, Mologic, however, hopes to be one of the first approved for the African market. It has announced plans to roll out a rapid test being developed in a collaboration with Senegal’s Institut Pasteur de Dakar as early as April.  The test is to be manufactured in Senegal by the pharma company DiaTropix, with prototypes to be ready in mid-April, according to the manager of DiaTropix, Cheikh Tidiane Diagne. 

Mologic has received £1 million to develop the test as part of the UK government’s £46 million international coronavirus (COVID-19) prevention and research funding package, and the aim is to manufacture the test for as little as £1.

While targeting Africa first, high-income countries swamped with Covid-19 cases will also benefit from the emergence of new rapid tests, said Mologic Medical Director Joe Fitchett, in the company’s press release.    

“The COVID-19 outbreak is at a critical juncture, and to bring it to an end, we need next- generation diagnostics for use at the point-of-need – at home or in the community, in limited and well-resourced settings,” he said. 

(HPW/Svet Lustig): COVID-19 test trends in selected high-income countries of WHO’s Americas (AMRO), African and South East Asia (EMRO) regions. Developed from national test data collected by FIND (finddx.org) as of 24 March, 2020.

Meanwhile, the worldwide network of some 10,000 GeneXpert® diagnostics – traditionally used to test for TB – may provide Africa and other low- and middle-income countries with another important interim solution.  A new COVID-19 test for the GeneXpert platform was just approved last week by the US FDA, and medicines access advocates are now calling for the test price to be reduce from $US 20 to $US 5 for the 145 low- and middle-income countries that procure GeneXpert tests at concessionary prices, under arrangements with donors and international agencies such as WHO and the The Global Fund to Fight AIDS, Tuberculosis and Malaria. 

“The GeneXpert® platform could fill a crucial need, especially in low- and middle-income countries,” Paula Fujwara, Scientific Director of the International Union Against Tuberculosis and Lung Disease (The Union), told Health Policy Watch on Monday. “The need for testing is immense as we still don’t know the true number of people who are infected in the world,” she added, and adapting the GeneXpert platforms in low- and  middle-income countries to COVID-19 testing could be “easily and rapidly done,” since the technology is already well-known.

Colombia: Ramping up Tests and Social Distancing Measures 

Medellin, Colombia’s second largest city

As of 18 March, fewer than 3,000 tests had been performed in Medellin; six days later the national number had grown to 7240 tests – with 378 cases confirmed. The largest case cluster was in the capital city of Bogota, while 52 cases have now been reported in Medellin, Colombia’s second largest city. 

In a comment to Health Policy Watch, Antioquia’s Secretary of Health, Luis Gonzalo Morales said, “We have test capacity at our regional laboratory in Antioquia to undertake the tests. Early this week we have begun the process. We have sufficient reagents to undertake the quantity of tests necessary based on the criteria that has been set by the Ministry of Health.” 

Zapata also credits the Antioquia regional governor, Anibal Gaviria, and Medellin Mayor Daniel Quintero, with strengthening policies on social distancing, which left streets in the city largely deserted over the recent bank holiday – as well as clearing the skies of persistent air pollution. Schools have been closed since mid-March, and public gatherings have been limited. 

Still, Medellin remains vulnerable to the COVID-19 pandemic given its high population density, as well as the scarcity of hospital beds, says Zapata. For instance, it has only 850 beds equipped with respirators for the city of 2.4 million people. Furthermore, 11.4% of Medellin’s population is above the age of 65, amounting to at least 250 000 elderly at risk, Zapata stresses. 

Nationwide, Colombia has only 1.7 regular hospital beds per 1000 people, according to official Health Ministry data, as compared to Cuba (5.1 beds), Uruguay (2.7) or Panama (2.3).

Venezuelan migrants flock to city hall, creating COVID-19 transmission risks, after fake news report of emergency financial handout circulate on social media.

Fake News Can Lead To More Infections 

More than a quarter of Colombia’s population is living below the poverty line. And in Medellin, especially, large migrant population of Venezuelan migrants remain vulnerable, including to misinformation. 

A recent fake WhatsApp message sent hordes of Medellin migrants running to the Municipality headquarters thinking that they would get a handout of money due to the COVID emergency.  Also, Medellin continues to face chronically high levels of air pollution due to forest fires burning in the north, notes Zapata.

Still, Zapata is hopeful that the recent pre-emptive measures, along with stepped up testing, are now having an impact. There are fewer people on the streets and in the buses.  And more than 100 technology volunteers working with a local non-profit initiative, #InnspiraMED, which has created three prototype mechanical ventilators from open-source technologies. The initiative aims to bring the prototypes to scale locally, as well as generating models that can be copied elsewhere around the world. 

Meanwhile, Zapata is now working from home along with his boss, Medellin Mobility Secretary, Carlos Cadena, directing  essential daily operations of traffic workers and contractors. Zapata is happy that at least air pollution had been reduced somewhat, as a result of the lighter traffic in the city. 

Cadena recently tested positive himself for COVID-19, trying to plan ways to reduce traffic and rationalize public transport flows, in ways that also reduce commuters’ infection risks. As a close contact, Zapata was tested — and is still awaiting results. 

Cadena, who shot an upbeat video message from isolation at home after being diagnosed, with a picture of a bicycle in the background, continues to work from home, while recovering. 

“He is ill, but he has remained on the front lines,” says Zapata. 

Carlos Cadena, Mobility Secretary, Medellin: will keep working from home, while recovering from COVID-19.

Image Credits: Diego Zapata , Busan Metropolitan City, Jade Lee, Singapore Ministry of Health, WHO AFRO/Otto B., HPW, Carlos Cadena.

Technician separates blood components into plasma, platelets, and red blood cells.

The US Food and Drug Administration granted investigational emergency use approval for convalescent blood plasma as a potential COVID-19 treatment on Tuesday. 

Cloned antibodies from recovered COVID-19 patients showed impressive ability to neutralize SARS-CoV-2, the virus behind the disease, in cell cultures, according to a paper published Wednesday on the preprint server BioRxiv. Two of the most potent antibodies isolated, 299 P2C-1F11 and P2B-2F6, were able to bind so strongly to the virus that it reduced the percentage of virus attaching to live cells by almost 100%. 

Patients who have recovered from COVID-19 have antibodies in their blood that might be effective against the infection. These antibodies, found in the blood plasma – or the transparent, liquid part of the blood – could be then injected into COVID-19 patients to provide some immunity as the host immune system ramps up its own response.

Early evidence from a Chinese trial in 10 patients showed “significant improvement” within 1 to 3 days after receiving a blood plasma transfusion, with 2 of the 3 patients weaned off mechanical ventilation shortly after the transfusion.

New York State, which has about half of the 62,873 COVID-19 cases in the United States, is set to roll-out the first treatments within the next week, Governor Andrew Cuomo said on Monday. According to CNN, New York will be first recruiting recovered patients from New Rochelle, which saw the first cluster of cases in the state and thus has the largest cluster of recovered COVID-19 patients eligible to donate blood. 

Although promising, convalescent blood plasma is not effective for every disease, says the US FDA, including for viral diseases such as Ebola. Success in cell culture studies must still be replicated in human patients. However, experts have been pushing since January for more serious consideration of such treatment as a potential COVID-19 treatment, based on limited success in treating other coronaviruses, such as SARS and MERS.

Under US FDA regulations, the treatment is only available to patients with a lab confirmed positive COVID-19 test experiencing severe disease, and enrolled in a clinical trial. 

A recovered patient with a prior lab-confirmed COVID19 diagnosis may donate blood plasma 2 weeks after their symptoms resolve, and only if they then test negative for COVID-19. 

The collected blood plasma can then be immediately infused into COVID-19 patients with severe disease, after the donation is screened for other blood-borne diseases.

Other trials of blood plasma or plasma-derived products are already taking place at the University of Washington in St. Louis, Missouri. Scientists there submitted a  investigational new drug application to the FDA on 18 March. In a related development, the pharma firm Takeda announced on 4 March that the company initiated development of an antibody treatment derived from plasma. 

61 Organizations Call On EU To Ensure Accessibility of New Coronavirus Products

Some 61 NGOs released an open letter on Wednesday calling on the European Union and national governments to incorporate access and affordability products into approvals for new COVID-19 products. The groups also said that governments should exclusive licensing, and require disclosure of public contributions to drug development as part of COVID-19 research.

“In the current pandemic situation when time is of the essence and it is critical that any treatment developed with public funds is made as widely available as possible, the call for greater transparency and accountability for public funds used in biomedical R&D is particularly pertinent,” said Jaume Vidal, senior policy advisor at Health Action International, the access organization that coordinated the letter, in an interview with Health Policy Watch.

Vidal added that making COVID-19 drugs as widely available as possible “necessarily entails” affordability requirements, and that the ask on non-exclusive licensing was a “specific demand to counter” medicines shortages, which can be caused by limiting the number of producers. 

A recent fast-track US $45 million call for proposals on developing therapeutics and diagnostics for COVID-19 by the Innovative Medicine Initiative (IMI) did not require affordability clauses, according to the letter. Affordability clauses help ensure that any successful products developed by grant money are not priced out of reach of low- or middle-income countries, or poorer health systems. 

Additionally, the NGOs said that granting exclusive licenses for successful COVID-19 product should not be allowed, just days after the US FDA granted Gilead’s remdesivir, a promising coronavirus antiviral, “orphan drug” status – giving the pharma company 7 years of US market exclusivity.

However in an unusual about-face, the company requested the FDA rescind the “orphan drug” designation on Wednesday after facing a public backlash from medicines access advocates.

The open letter said that market exclusivity on COVID-19 products could create “excessively high prices or over-reliance on a single source, which can increase the possibility of shortages.

“An effective response requires that all these necessary medical tools are free of charge at the point of delivery, particularly for vulnerable populations,” the organizations stated in the letter.

Europe Remains the Epicentre, But Some Countries Can Still Stem the Tide.

The letter was released as active cases in Europe surged to 197,842 cases and 12,822 total deaths. Italy and Spain remain the worst affected countries with 54,030 and 40,382 active cases respectively; however, Switzerland with 9765 cases has now overtaken Italy to have the highest number of cases per capita. 

In Italy, fatalities rose to 743 deaths, after several days of lower numbers. Prime Minister Giuseppe Conte increased fines for leaving homes to up to 3,000 euros from the previous maximum of 206 euros. In Spain, an ice rink in Madrid has been converted into a temporary morgue, according to El Paiz.

Meanwhile, across the Atlantic, cases shot up in the United States to 62,873, with 30,811 alone in New York State. The uptick of cases in the state is also driven by increased testing. The state is testing more than 16,000 people a day, a higher per capita testing rate than even China or South Korea, according to a press release from Governor Andrew Cuomo’s office. However, other states in the US are still facing test kit shortages – amid mixed messages from the White House on whether most US workers will be able to return to their jobs again by Easter.

In Latin America, Brazil remains the most affected country at 2155 cases followed by Chile with 903 and Ecuador with 775 cases. As the number of cases escalates in Chile, the government is facing pressure to introduce a national lockdown, following in Argentina’s footsteps, according to National Public Radio. Chilean President Sebastian Piñera has declared the situation as “a state of catastrophe” and has deployed the armed forces to maintain infrastructure and supply lines. 

According to the latest WHO situation report, the total number of cases in the WHO African Region is 1305 -315 more than the previous day – and deaths increased from 23 to 26. South Africa, Algeria and Burkina Faso are the most affected countries in the region with 402, 231 and 99 cases respectively. President of the Democratic Republic of the Congo Felix Tshisekedi declared a “state of emergency” Wednesday morning as the case count hit 45 cases and 3 deaths, closing country borders and banning all flights, even domestic ones, from entering Kinshasa, in an attempt to lock down the country’s dense urban center.

However, according to World Health Organization Director General Dr Tedros Adhanom Ghebreyesus, around the world more than 150 countries still have less than 100 cases – and those nations still had a chance to prevent widespread disruptions from COVID-19.

“Aggressive measures to find, isolate, test, treat and trace are not only the best and fastest way out of extreme social and economic restrictions – they’re also the best way to prevent them,” said Dr Tedros.

Active cases around the world as of 11PM CET 25 March. Right column shows cumulative case count. Numbers are rapidly changing.

This story was updated 27 March 2020.

Image Credits: Banc de Sang i Teixits, Johns Hopkins CSSE.

Healthcare worker runs a test on a GeneXpert machine.

Médecins Sans Frontiéres (MSF) on Tuesday launched a campaign to push for a US $5 price tag on a new COVID-19 rapid diagnostic test that can be used on GeneXpert, a diagnostic instrument widely deployed around the world for diagnosing tuberculosis. 

The test for SARS-CoV-2, the virus that causes COVID-19, received US Food and Drug Administration emergency use approval just last Friday, and represents a hope for scaling up COVID-19 testing in low- and middle-income countries.

The MSF announcement coincided with World Tuberculosis Day, and reflected one of the many ways in which the battle against one of the world’s oldest respiratory diseases, TB and the battle against the newest threat to lung health from COVID-19, are now converging. 

The Xpert Xpress SARS-CoV-2 Test for testing for the novel coronavirus should be no more than $5 a cartridge,” said Sharonann Lynch, HIV and TB Policy Advisor at Médecins Sans Frontiéres/Doctors Without Borders’ Access Campaign, in an interview with Health Policy Watch

The US company that produces GeneXpert tests Cepheid has set the coronavirus test price at $19.80 per cartridge for 145 developing countries, according to Lynch. In high income countries, the coronavirus test will cost $35 per cartridge. 

The TB test for the platform currently costs $9.98 per cartridge for low- and middle- income countries. An HIV diagnostic test, which can also be performed on the platform, costs $14 per cartridge.

However, even the US $10 price on the TB test is too high for many countries, said Lynch. Thus, Cepheid could “drastically lower the price to $5 per test.”

An assessment of other GeneXpert tests by MSF and Cambridge Consultants found that a US $5 price tag per cartridge could still generate profit for Cepheid, as the ‘cost of goods’ – or the cost of materials, manufacturing, labour, overhead, intellectual property, and other indirect expenses – is estimated to be only  US $3. The campaign for a $US 5 coronavirus test is an extension of an existing ‘Time for 5’ campaign by MSF to knock down prices for TB and HIV test cartridges to US $5 a piece.

WHO Releases New Guidelines For Preventative TB Treatment

Also on World Tuberculosis Day, the World Health Organization released new guidelines to scale up new, and dramatically shorter preventative regimens for latent tuberculosis (TB), one of mankind’s oldest and deadliest diseases.

“COVID-19 is highlighting just how vulnerable people with lung diseases and weakened immune systems can be,” said WHO Director-General Dr Tedros Adhanom Ghebreyesus in a press release. “Millions of people need to be able to take TB preventative treatment to stop the onset of disease, avert suffering, and save lives.”

In the context of the COVID-19 pandemic, “early evidence suggests that people with TB will be more susceptible to coronavirus and severe COVID-19,” said Lynch. 

Thus, scaling up preventative TB treatment could also help reduce negative impacts of the rapidly accelerating COVID-19 pandemic according to the WHO, which has also released guidance on how to sustain TB treatment during the COVID-19 emergency.

Tuberculosis remains the world’s top infectious killer – in 2018 there were an estimated 10 million new symptomatic infections and 1.5 million deaths.

About a quarter of the world’s population is estimated to be infected with TB bacteria, but are not sick nor contagious. However, those with such “latent” TB are at higher risk of developing active disease, which can be particularly deadly in immunocompromised people. 

Treating latent TB remains the most effective strategy to prevent the progression to active disease and protect others against onwards transmission – but has been largely neglected as a part of TB control programmes. To date, only 430,000 of the target 24 million contacts of people with active TB and only 1.8 million of the target 6 million people living with HIV have received preventative treatment.

The new WHO guidelines recommend new shorter regimens for preventative treatment for latent forms of the disease, ranging from a 1 month daily rifapentine/isoniazid treatment to 4 months of daily rifampicin alone – shaving off months from the previous standard 6-month isoniazid treatment. 

The guidelines also recommend the rapid scale-up of preventative TB treatment among populations at highest risk, including household contacts of TB patients, people living with HIV, and those with lowered immunity or living in crowded settings; integrating TB preventative treatment into case-finding efforts for active TB, and using tuberculin skin tests or an interferon-gamma release assay (IGRA) to test for infection when tests are available.

Woman puts on a facemask at a healthcare facility for drug-resistant TB patients in New Delhi, India

Leveraging TB Knowledge To Fight COVID-19

As the COVID-19 pandemic accelerates, the World Health Organization and leading TB organizations also are promoting a joint approach to tackling both the world’s oldest and newest respiratory threats. 

New WHO guidance for TB programme directors recommends leveraging TB prevention strategies, technologies and logistics, and programmatic staff to tackle the diseases. 

TB staff, with years of experience in low-resource settings, are well positioned to offer technical assistance in contact tracing and active case finding, the cornerstones of a robust COVID-19 response. 

We know what works to fight COVID-19 from our experience and the tools we have developed to end TB: infection control, wide-spread testing, contact tracing, X-rays, artificial intelligence, telemedicine and psycho-social support,” said José Luis Castro, executive director of The International Union Against TB and Lung Diseases (The Union) in a press release.

However, some TB advocates have also expressed concerns that the global focus on COVID-19 could shift resources from essential TB treatment services. 

“The COVID emergency should marshall all necessary resources, but not at the expense of TB services, including TB testing, or people with TB,” said Lynch.

Additionally, with countries enacting more strict travel restrictions in the face of accelerating COVID-19 outbreaks, it may be time to try a new model of care for TB patients

For those with active TB, a full treatment course is at least 6 months and treatment is usually directly observed by providers, which means patients or healthcare workers must travel daily to meet in clinics or homes to administer treatment. 

“To reduce the risk for existing patients, [we] must seek ways to re-design models of care to provide treatment for people with TB in the community and use remote telemedicine and web apps to support them,” Lynch suggested.

Image Credits: WHO/UNITAID, CNS Images.

Carlos Alvarado Quesada, President of Costa Rica

Costa Rica’s president, Carlos Alvarado Quesada has appealed to Dr Tedros Adhanom Ghebreyesus, Director General of the World Health Organization, to “pool rights to technologies that are useful for the detection, prevention, control and treatment of the COVID-19 pandemic”.

The presidential letter dated Monday, 23 March, and co-signed by Minister of Health, Daniel Salas Peraza, proposed that the global pool “should include existing and future rights in patented inventions and designs, as well as rights in regulatory test data, know- how, cell lines, copyrights and blueprints for manufacturing diagnostic tests, devices, drugs, or vaccines”.

“It should provide for free access or licensing on reasonable and affordable terms, in every member country.”

In the letter, first published by the advocacy group, Knowledge Ecology International, Costa Rica also echoed an earlier request by Chile for the WHO’s Global Observatory to compile a comprehensive database to document all R&D activity related to COVID-19 with clinical trial cost estimates, and the subsidies provided by governments and charities.

“Improving transparency through the Global Observatory on Health R&D, as mandated in the resolution, would allow us to better understand the costs of developing these technologies and what roles are being played by each actor” ,said Luis Villaroel, Director of Corporación Innovarte in Chile, an advocacy group, in a statement.

Compulsory licenses that override existing or future patents on promising COVID-19 treatments have been approved or are under consideration by a growing number of nations, including Costa Rica, Chile, Colombia, Peru, Malaysia, the Netherlands and Israel, to enable their citizens to gain access to patented medical products related to Covid-19 at an affordable price.

Last Friday, a resolution to issue compulsory licenses was approved by a committee in Ecuador’s National Assembly. 

“If in situations like the current one, the intellectual property system cannot provide solutions for the benefit of the population, we should necessarily rethink the model”, said Hernan Nuney, the executive director of the Ecuadorian Institute for Intellectual Property to Knowledge Ecology International, an advocacy group focused on patent and medicine issues.

Under the Trade-Related Aspects of Intellectual Property Rights (TRIPS) agreement of the World Trade Organization (WTO), a country can approve a compulsory licence to a generic drug maker or public agency to enable a patented medicine to be produced without the brand-name company’s consent. In other words, a compulsory licence can suspend a monopoly run on a patent, enabling others than the patent holder to manufacture and to supply the product.

Last week, US drugmaker AbbVie waived worldwide restrictions on its Lopinavir/Ritonaivr HIV combination drug, marketed under the brand name Kaletra, which is now being studied as a treatment for COVID-19.

“Given this important public health crisis, AbbVie commits that we will take all steps necessary to remove any potential barriers to alternate sources of supply, including dedicating to the public our intellectual property related to lopinavir/ritonavir”, said an AbbVie spokeswoman.

Abbvie represents the first large drugmaker to have prioritized provision of the medicine around the world over potential financial gains from potential COVID-19 treatments. Kaletra had patent protection until at least 2026 in certain regions, according to MedsPaL, a medecines patents and licenses database. 

However, a study of 199 hospitalized patients published in the New England Journal of Medicine found that the lopinavir/ritonavir combiation only led to a median 1 day improvement in patients’ outcomes over the standard of care, leading authors to conclude that there was essentially “no benefit” of the treatment over standard of care, although they said that future trials in patients with severe illness would still be needed to exclude or confirm the drug’s potential.   

The findings, were “not unexpected” because these antiretroviral drugs [lopinavir/ritonavir] are not at all targeted to coronavirus proteins – this was always something of a long shot”, said one Derek Lower in a blog in Science Translational Medicine.  Even so, a day later, Israel approved the issuance of a compulsory license for generic versions of the drug should it be needed for COVID-19 treatment, saying that the decision to override the patent rights still in force locally until 2024 was justified insofar as the Kaletra formulation is currently unavailable. 

“The company with the patent and official importer in Israel are not able to supply the necessary inventory for this drug,” said the Justice Ministry in a statement explaining the decision. “The state will be able to import generic substitutes from countries where the patent has expired.”

Despite AbbVie’s subsequent decision to waive patent rights, the Israeli move was regarded as an important precedent among medicines access advocates, which noted that Israel is a member of the Organisation of Economic Development and Co-Operation (OECD), and OECD member states rarely override patent rules.  

A comprehensive list of therapies for Covid-19 can be found here. While many are already existing drugs that are being tested for efficacy against the SARS-CoV2 virus, there are also some two dozen new therapeutics in the pipeline as well as over 60 COVID-19 vaccine candidates. 

Some of the top candidates are the focus of a WHO-organized SOLIDARITY trial, which was announced last week, as an umbrella effort to bring disparate clinical trials together.  These top candidates include remdesivir, originally developed by Gilead Pharmaceuticals as a treatment for Ebola, for which it failed to show results. But in the case of COVID-19, there have been scattered observational reports showing improvement, and it is currently the focus of at least five separate clinical trials. A third leading candidate is the antimalarial drug hydroxychloroquine, in combination with the antibiotic, azithromycin.  Initial, positive results from a small French trial were reported late last week, involving a total of 42 patients, 26 of whom received the experimental drug combination, with a significant reduction in viral loads amongst 20 patients who received the full course of treatment.  

Rush For Treatments Comes Against Rising Cases in Europe, Americas, Africa & South-East Asia 

The rush to find treatments came against the sharp rise of cases seen worldwide almost everywhere outside of western Asia, and now approaching half a million mark.

The biggest new regional uptick was now being seen in Latin America and the Caribbean, where some 5317 cases had been recorded as of the 24th of March, along with 57 deaths. Brazil and Chile accounted for the most cases with 1857 and 733 people affected. Argentina, Bolivia, the Brazilian state of São Paulo and Colombia have introduced obligatory nationwide (or statewide) quarantine while others have curfews in place. Meanwhile, Brazil and Uruguay have sealed their border to prevent incoming visitors to Brazil. 

As the coronavirus spreads in Brazil and Colombia, indigenous tribes are closing off their reserves to visitors. Though no cases have been confirmed yet among the indigenous populations, tribes that have limited interaction with outsiders have historically experienced low immunity against respiratory diseases in general. Therefore, “with the coronavirus threat, there is the possibility of really exterminating an entire people”, warns Paula Vargas, Brazil program manager for Amazon Watch, an indigenous rights group. 

Regionally, Africa was also showing a significant increase in transmission, with 1396 confirmed cases in 43 countries. Egypt, South Africa and Algeria have the highest number of cases with 294, 274 and 201 infections respectively. 

In Italy, 5,246 new cases had been reported over the past 24 hours. However, for the third day running, new cases remained below the peak of 6,600 new cases on Saturday 21 March, leaving some hopes that trends might be steadying out in the country of 60 million people that has experienced almost as many cases as in China’s population of 1.4 billion. Per capita, Switzerland’s cases were closely following those of Italy, with about 900 infections per million people, according to the latest data, although some of the increase could be attributed to more extensive testing than elsewhere in Europe. Switzerland has recently tightened its border controls, and was ramping up other response measures.

Global tracking of active cases of COVID-19 (middle) around the world as of 19:31 PM CET 24 March. Numbers change rapidly.

France Access Group Protests Health Ministry Inertia on COVID-19 Testing  

In neighboring France, Minister of Health, Oliver Veran, came under fire on Monday after saying that France would not undertake massive testing for COVID-19 until the current lockdown was over, and newer rapid tests, as well as blood tests to identify people that have antibodies to the virus were developed.

In a press statement, the French Observatory for Medicines Transparency, denounced Veran’s policy as contradicting WHO.

“The WHO has not said ‘wait for serological tests’, the WHO has said ‘test, test, test,’ protested Pauline Londeix, co-founder of the group. 

“Widescale testing would help identify COVID-19 in groups such as health workers, cleaners, and store clerks, who might have light or asymptomatic cases but could potentially infect many others if they were not identified, allowing them to isolate themselves, recover and protect others,” she said.

“The more days that pass, the more it appears clear to us that pseudo-medical decisions have been taken by the [French] government concerning COVID-19 testing, due to economic considerations, first and foremost.  Our country, one of the seven largest industrial powers in the world, and supposedly blessed with an important biomedical industrial sector, is continually out of step, and constantly being forced to improvise”, Londeix added.

She said the government should elaborate a clear test strategy and ramp up national public production of test kits, including reagents and their raw materials, as well as alcoholic gel and protective masks for health workers as soon as possible. 

Although patents on most of the standard, low-throughput PCR technologies, the letter also expressed concerns that control over high-volume diagnostic test tools remains concentrated in the hands of a few key pharma and diagnostic test manufacturers, such as Roche, Abottt/Alere, Biomérieux, Quiagen and Thermo Fisher, who hold the rights to their respective test platforms. 

Gauri Saxena contributed to this story 

Image Credits: Johns Hopkins CSSE.

Staff members administering vaccinations at Kabuga Health Center in the Gasabo district of Kigali (Rusororo sector), Rwanda on June 28, 2018.

As the explosive impact of COVID-19 ripples globally, there’s a clear plea from many regions and countries: stay home and help “flatten the curve” of infection. People from China to Italy have seen the consequences of the virus spreading too quickly with hospitals overwhelmed and doctors forced to make heartbreaking decisions about who lives and dies.

It’s natural to hear these stories and blame a lack of pandemic preparedness. But emergency response can only go so far if the health system’s first line of defense – primary health care – isn’t up to the task.

Experts have already called attention to gaps in front line health supplies, such as masks, hand sanitizer, testing kits and vaccines. In the U.S., where we live, these gaps mean we’re now fighting a steep uphill battle in containing the virus. But few are talking about shortcomings of the primary health care system, which is about far more than just supplies. Strong primary health care looks like a trusted nurse or doctor, who is always there and trained to answer your questions. It means comprehensive quality care – in one place – tailored to your health needs. It means confidence that your local health center is safe and ready with quality medicines and supplies, regardless of outbreaks or changes in the world around you.

Whether or not a crisis is looming, primary health care should be the first place everyone turns for health services or information, using hospitals only when truly necessary.

For most people worldwide, though, access to quality primary health care depends on where you live or how much money you have. In fact, primary health care is chronically underfunded and deprioritized in rich and poor countries alike.

COVID-19 has made it painfully clear that we can’t afford to have weak primary health care continue as our reality. In the U.S., fragmented care and lack of clear communication from experts has left people anxious about where to turn, making unnecessary visits to emergency rooms. In Italy, where the health care system has experienced cuts in funding over the past decade, we’re seeing the dire consequences of having too few staff and supplies. And across Africa, where the virus is rapidly spreading, misinformation and mistrust of health systems could keep people from seeking care – as we saw in Liberia and other West African countries during the 2014-2016 Ebola outbreak.

This doesn’t have to be the case. There are clear steps the world can take to fully unlock the potential of primary health care, both to help us respond to the current pandemic and prepare for disease outbreaks we’ll inevitably face in the future.

In the short-term, primary care providers should be considered central partners and first responders in this crisis, helping to test and triage the most at-risk patients, and reducing the burden on already-overwhelmed hospitals. Leaders owe them reliable information and tools, including additional support for logistics and staffing and critical supplies such as rapid test kits and personal protective equipment. Such approaches have paid off in a big way in countries like Singapore, where they’ve been able to mobilize a trusted and well-resourced primary health care workforce.

Trusted primary care providers can also play a key role disseminating prevention messages to the public and high-risk groups, and encouraging social distancing by offering telehealth services for people with COVID-19 symptoms and chronic disease patients alike.

In the weeks and months ahead, countries and donors should also resist the urge to earmark all response funds for coronavirus-specific care. As health systems approach breaking point, flexible funds for primary health care can aid the response and prevent disruptions to essential daily life-saving services, from delivering babies to treating chronic conditions. This approach will also help head off future epidemics, rather than promote a continuous cycle of “Band-Aid” investments that ignore the root of the problem.

In the long term, governments must significantly increase spending on quality primary health care to make sure it’s well-resourced and affordable – so that no one has to choose between seeking care and paying their bills. The World Health Organization estimates that it will take an additional $200 billion annually to fund quality primary health care for all; well-spent, this could save 60 million lives in low- and middle-income countries alone.

Finally, we can’t fix problems that we can’t diagnose. Countries desperately need better ways to take the temperature of their primary health care systems. At the Primary Health Care Performance Initiative, a partnership of country policymakers, health systems managers and advocates, we’re working with governments around the world to collect more and better data, equipping leaders to pinpoint weaknesses and improve health systems before the next pandemic hits. Counting treatments or people infected is not enough – we need to know if people trust and value their care; if health workers are trained, resourced and motivated; and if clinics are safe, clean and well-managed.

We are only as prepared as the world’s weakest health system. The world has repeatedly failed to learn this before. We must do better beginning today, or this won’t be the last time we pay the price.

______________________________________________________________________________

Dan Schwarz, MD MPH is the Director of Primary Health Care at Ariadne Labs and an Adviser to the WHO and the Lancet Commission on Noncommunicable Diseases and Poverty, with over a decade of experience in global healthcare delivery. 

 

 

 

Beth Tritter is the Executive Director of the Primary Health Care Performance Initiative (PHCPI). PHCPI was founded in 2015 by the Bill & Melinda Gates Foundation, the World Health Organization and the World Bank Group, and now including UNICEF, in collaboration with Ariadne Labs and Results for Development. She previously served in the U.S. government as the Millennium Challenge Corporation’s Vice President for Policy and Evaluation.

Image Credits: Bill & Melinda Gates Foundation/Samantha Reinders.